Common use of INCORPORATION OF CERTAIN INFORMATION BY REFERENCE Clause in Contracts

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENT

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to We “incorporate by reference” into this prospectus the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documentsthe documents that contain such information. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information Information that we file later subsequently with the SEC will automatically update and supersede this prospectus. In other words, in the case of a conflict or inconsistency between information set forth in this prospectus and/or information incorporated by reference into this prospectus, you should rely on the information contained in this prospectus and any accompanying prospectus supplementthe document that was filed later. We incorporate by reference the documents listed below that and any filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, (i) after the initial filing of the registration statement that contains this prospectus and prior to effectiveness of such registration statement, and (ii) on or after the date of this prospectus and prior to the termination of the offering made pursuant to this prospectus: ● our • Our Annual Report on Form 10-K for the fiscal year ended December 31February 3, 20162024, filed with the SEC on March 826, 2017; ● our Quarterly Reports 2024, as amended by the Annual Report on Form 10-Q for K/A filed with the fiscal quarters ended SEC on March 3127, 20172024 (together, the “Annual Report”); • The information specifically incorporated by reference into our Annual Report from our definitive proxy statement on Schedule 14A, filed with the SEC on May 9, 2017, June April 30, 20172024; • Our Current Reports on Form 8-K, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 20172024 and April 4, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2024; and ● the • The description of our Class A common stock contained in our Registration Statement on Form 8-AA filed October 3, filed on April 14, 20152005, including any amendments thereto amendment or reports report filed for the purposes of updating this description. All reports and other documents that we file with the SEC for the purpose of updating such description. Nothing in this prospectus shall be deemed to incorporate information furnished to but not filed with the SEC pursuant to Item 2.02 or Item 7.01 of Form 8-K (or corresponding information furnished under Sections 13(aItem 9.01 or included as an exhibit to Form 8-K). We encourage you to read our periodic and current reports. We think these reports provide additional information about our company which prudent investors find important. We will provide to each person, 13(c)including any beneficial owner, 14 to whom a prospectus is delivered, at no cost, a copy of any or 15(d) all of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be documents that are incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will but not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of delivered with this prospectus, upon written or oral requesttelephonic request to us at our principal executive offices at the following telephone number and address: 000 Xxxxxxxx Xxxxxxx, a copy of all Xxxxxxxxx, Xxxxx 00000, (000) 000-0000, Attn: Investor Relations. You should rely only on the information incorporated by reference or provided in this prospectus, any supplement to this prospectus or any other offering materials we may use. We have not authorized any person to provide information other than that provided in this prospectus, any supplement to this prospectus or any other offering materials we may use. You should assume that the information in this prospectus, any prospectus supplement and any other offering materials we may use is accurate only as of the preceding date on its cover page and that any information in a document we have incorporated by reference is accurate only as of the date of the document incorporated by reference. The statements that we make in this prospectus or in any document incorporated by reference in this prospectus about the contents of any other documents are not necessarily complete, and are qualified in their entirety by referring you to copies of those documents that are filed as exhibits to the registration statement, of which this prospectus forms a part, or as an exhibit to the documents incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)reference. You may request a copy can obtain copies of these materials in documents from the manner set forth under the heading “Additional Information,” SEC or from us, as described above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENT.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 816, 20172020; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Definitive Proxy Statement on Schedule 14A 14A, filed with the SEC on April 109, 20172020; ● our Current Reports on Form 8-K filed with the SEC on February 287, 20172020, March 3010, 20172020, May 26April 1, 20172020, August 22as amended by the Amendment on Form 8-K/A filed with the SEC on April 21, 20172020, October 17and April 7, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2020 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock stock, par value $0.0001 per share, contained in our Registration Statement on Form 8-A, A filed on April 14, 2015, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to PROSPECTUS Xxxxxx Pharmaceuticals Holdings, Inc. $150,000,000 200,000,000 Common Stock Preferred Stock Warrants Debt Securities Subscription Rights Units We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock, which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi) units. The debt securities may consist of debentures, notes, or other types of debt. The debt securities, preferred stock, warrants and subscription rights may be convertible into, or exercisable or exchangeable for, common or preferred stock or other securities of ours. The units may consist of any combination of the securities listed above. The aggregate public offering price of the securities that we are offering will not exceed $200,000,000. We will offer the securities in an amount and on terms that market conditions will determine at the time of the offering. Our common stock is listed on the Nasdaq Global Market under the symbol “CRBP.” The last reported sale price for our common stock on January 4, 2018 as quoted on the Nasdaq Global Market was $8.35 per share. You are urged to obtain current market quotations of our common stock. We have no preferred stock, warrants, debt securities, subscription rights or units listed on any market. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. Investing in our securities involves risk. You should carefully consider the risks that we refer you to under the section captioned “Risk Factors” in this prospectus on page 3 before buying our securities. Should we offer any of the securities described in this prospectus, we will provide you with the specific terms of the particular securities being offered in supplements to this prospectus. You should read this prospectus and any supplement, together with additional information described under the headings “Additional Information” and “Incorporation of Certain Information by Reference” carefully before you invest. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement. We may sell these securities directly to our stockholders or to other purchasers or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is January 17, 2018 TABLE OF CONTENTS ABOUT THIS PROSPECTUS SUPPLEMENT1 RISK FACTORS 3 PROSPECTUS SUMMARY 1 USE OF PROCEEDS 28 FORWARD-LOOKING STATEMENTS 28 THE SECURITIES WE MAY OFFER 30 RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS 29 DESCRIPTION OF STOCK WARRANTS 33 DESCRIPTION OF CAPITAL STOCK 30 DESCRIPTION OF SUBSCRIPTION RIGHTS 39 DESCRIPTION OF DEBT SECURITIES 34 FORMS OF SECURITIES 41 DESCRIPTION OF UNITS 40 LEGAL MATTERS 46 PLAN OF DISTRIBUTION 43 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 46 EXPERTS 46 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 48 ADDITIONAL INFORMATION 47 Xxxxxx Pharmaceuticals Holdings, Inc. is referred to herein as “Xxxxxx,” “the Company,” “we,” “us,” and “our,” unless the context indicates otherwise. You may only rely on the information contained in this prospectus and the accompanying prospectus supplement or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the securities offered by this prospectus and the prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus or any prospectus supplement nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or such prospectus supplement or that the information contained by reference to this prospectus or any prospectus supplement is correct as of any time after its date. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (“SEC”) using a “shelf” registration process. Under this shelf registration process, we may from time to time offer and sell, in one or more offerings, any or all of the securities described in this prospectus, separately or together, up to an aggregate offering price of $200,000,000. This prospectus provides you with a general description of our securities being offered. When we issue the securities being offered by this prospectus, we will provide a prospectus supplement (which term includes, as applicable, the at-the-market sales agreement prospectus filed with the registration statement of which this prospectus forms a part) that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional information described under the heading “Additional Information” and “Incorporation of Certain Information by Reference.” PROSPECTUS SUMMARY The following summary highlights some information from this prospectus. It is not complete and does not contain all of the information that you should consider before making an investment decision. You should read this entire prospectus, including the “Risk Factors” section on page 3 and the disclosures to which that section refers you, the financial statements and related notes and the other more detailed information appearing elsewhere or incorporated by reference into this prospectus before investing in any of the securities described in this prospectus. About Us We are a clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Our product anabasum is a novel synthetic oral endocannabinoid-mimetic drug that is intended to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum has generated positive clinical data in three consecutive Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Anabasum is also being evaluated in open-label extension studies in systemic sclerosis and skin- predominant dermatomyositis and in a Phase 3 study in systemic sclerosis, and we are currently planning for and finalizing the design of a Phase 2b study in cystic fibrosis and expect to commence the study in the first quarter of 2018. Anabasum is a synthetic, rationally-designed oral small molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2, found on activated immune cells, fibroblasts and muscle cells. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous pathways. These endogenous resolution pathways are normally activated in healthy individuals during the course of normal immune responses but are dysfunctional in patients with chronic inflammatory and fibrotic diseases. Through its activation of the CB2 receptor, anabasum is designed to drive innate immune responses from the activation phase through completion of the resolution phase. The CB2 receptor plays an endogenous role in modulating and resolving inflammation by, in effect, turning heightened inflammation “off” and restoring homeostasis. We are currently developing anabasum to treat four life-threatening diseases: systemic sclerosis; cystic fibrosis; diffuse cutaneous, skin-predominant dermatomyositis; and systemic lupus erythematosus, or SLE. The United States Food and Drug Administration, or the FDA, has granted anabasum Orphan Designation as well as Fast Track Status for both cystic fibrosis and systemic sclerosis. The European Medicines Authority, or the EMA, has granted anabasum Orphan Designation for both cystic fibrosis and systemic sclerosis. Recent Developments

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that from other documents we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documents. The documents instead of having to repeat the information incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that and any future filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act on or after the date of this prospectus (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules) until the termination of the registration statement of which this prospectus is a part: ● our • Our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC on March 8February 28, 20172022; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Our Current Reports on Form 8-K filed with the SEC on January 11, 2022 and February 2825, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● the • The description of our common stock contained in our the Registration Statement on Form 8-AA filed with the SEC on December 9, filed on April 14, 20152020, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a)Any statement contained in this prospectus, 13(c)or in a document all or a portion of which is incorporated by reference, 14 shall be modified or 15(d) of the Exchange Act after the date superseded for purposes of this prospectus but before to the termination of the offering of the securities hereunder will also be considered to be extent that a statement contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus or any document incorporated by reference into modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus. Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus from the date is delivered a copy of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered documents incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus, at no cost by writing or telephoning us at the manner set forth under following: BioAtla, Inc. 00000 Xxxxxxxxx Xxxx Xxx Xxxxx, Xxxxxxxxxx 00000 (000) 000-0000 Attn: Investor Relations You may also access these documents, free of charge on the heading SEC’s website at xxx.xxx.xxx or on the “Additional Information,Investor Relations” abovepage of our website at xxx.xx.xxxxxxx.xxx. Up to Information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus or any accompanying prospectus supplement. $150,000,000 100,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Jefferies

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “"incorporate by reference” " information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The documents instead of having to repeat the information incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that and any future filings (including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we have previously filed will make with the SEC: ● SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K): • our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9March 6, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172018; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May January 26, 20172018 and February 2, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2018; and ● • the description of our common stock contained stock, which is registered under Section 12 of the Exchange Act in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14October 3, 20152000, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may can request a copy of these materials filings, at no cost, by writing or telephoning us at the following address or telephone number: Rigel Pharmaceuticals, Inc. Attn: Vice President, Finance 0000 Xxxxxxxx Xxxx. South San Francisco, CA 00000 (000) 000-0000 This prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more information about us and the shares in this offering. Because information about documents referred to in this prospectus is not always complete, you should read the manner set forth under full documents which are filed as exhibits to the heading “Additional Information,” aboveregistration statement. Up to You may read and copy the full registration statement and its exhibits at the SEC's public reference rooms or its website. Table of Contents $150,000,000 65,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Jefferies

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits included in the registration statement of which this prospectus is a part for further information about us and the securities we are offering. You may read or obtain a copy of the registration statement from the SEC in the manner described above. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. The SEC allows us to “incorporate by reference” reference information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information this information. Information contained in this prospectus and any accompanying prospectus supplementsupersedes information incorporated by reference that we have filed with the SEC prior to the date of this prospectus. We incorporate by reference the following documents under SEC file number 001-32508 listed below that we have previously filed with (excluding any document or portion thereof to the SEC: ● our extent such disclosure is furnished and not filed): • Our Annual Report on Form 10-K for the fiscal year ended December March 31, 2016, 2016 filed with the SEC on March 8July 13, 20172016; ● our • Our Quarterly Reports Report on Form 10-Q for the fiscal quarters period ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, 2016 filed with the SEC on August 912, 2017 and September 30, 2017, filed with the SEC on November 8, 20172016; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Our Current Reports on Form 8-K and Form 8-K/A as filed with the SEC on February 28April 1, 20172016, March 30April 7, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2016 (other than any portions information furnished pursuant to Item 7.01 thereof deemed and related Exhibit 99.1), April 15, 2016, April 25, 2016, May 2, 2016, May 2, 2016, July 22, 2016 (other than information furnished pursuant to Item 7.01 thereof and not filedrelated Exhibit 99.1); , August 12, 2016 (other than information furnished pursuant to Items 2.02 and ● the 7.01 thereof and related Exhibit 99.1), August 23, 2016 (other than information furnished pursuant to Item 7.01 thereof and related Exhibit 99.1), August 25, 2016 (other than information furnished pursuant to Item 7.01 thereof and related Exhibit 99.1), August 31, 2016 (other than information furnished pursuant to Item 7.01 thereof and related Exhibit 99.5), September 8, 2016, September 27, 2016, October 3, 2016, October 6, 2016 and October 12, 2016 and 39 • The description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on April 14February 13, 20152008 pursuant to Section 12(b) of the Securities Exchange Act, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All In addition, we incorporate by reference all reports and other documents that we file with the SEC Securities and Exchange Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, (a) after the initial filing date of the registration statement of which this prospectus but before is a part and prior to the effectiveness of the registration statement and (b) after the effectiveness of the registration statement and prior to the termination of the offering of the securities hereunder this offering, and all such reports and documents will also be considered deemed to be incorporated by reference into this prospectus herein and to be a part hereof from the date of the filing of these such reports and documents, documents (except for information and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered furnished under Items 2.02 or 7.01 of our current reports on Form 8-K). Any document or statement incorporated by reference into herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement. Any document or statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. These documents contain important information about us, our business and our financial condition. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives a copy of , to whom this prospectusprospectus is delivered, upon written or oral requestrequest of such person, a copy of any or all of the preceding foregoing documents that are incorporated herein by reference reference. Requests for documents should be submitted to the Corporate Secretary at Xxxxx Energy, Inc., 000 Xxxxx Xxxx, Xxxxx 000, Xxxxxxx, Xxxxx 00000, or by telephone at (other than exhibits, unless 000) 000-0000. The foregoing documents also may be accessed on the exhibits are specifically incorporated by reference into these documents). You may request a copy investor relations page of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTour website at xxx.xxxxxxxxxxx.xxx.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to We “incorporate by reference” into this prospectus and any applicable prospectus supplement certain information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and Certain information that we subsequently file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementin our other filings with the SEC. We incorporate by reference the documents listed below that below, which we have previously already filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that future filings we file make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after Act, until all the date of securities offered by this prospectus but before have been sold and all conditions to the termination consummation of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documentssuch sales have been satisfied, and will supersede the information herein; provided, however, that all reports, exhibits and other information except that we “furnish” to are not incorporating any information included in a Current Report on Form 8-K that has been or will be furnished (and not filed) with the SEC, unless such information is expressly incorporated herein by a reference in a furnished Current Report on Form 8-K or other furnished document: • our Annual Report on Form 10-K for the fiscal year ended February 26, 2022, filed with the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy on April 21, 2022; • our Quarterly Report on Form 10-Q for the quarter ended May 28, 2022, filed with the SEC on June 29, 2022; • portions of this prospectusour Definitive Proxy Statement on Schedule 14A filed with the SEC on June 1, upon written or oral request, a copy of all of the preceding documents 2022 that are incorporated by reference (other than exhibitsinto Part III of our Annual Report on Form 10-K for the fiscal year ended February 26, unless 2022; • our Current Reports on Form 8-K filed with the exhibits are specifically incorporated by reference into these documents)SEC on May 27, 2022, June 29, 2022, July 15, 2022 and August 31, 2022; and • the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on May 11, 1992, including any amendment or report filed with the SEC for the purpose of updating such description. You may request a copy of these materials filings at no cost, by writing or calling us at the following address: 000 Xxxxxxx Xxxxxx, Xxxxx Xxx Xxxxxx 00000, telephone: (000) 000-0000, Attention: Investor Relations. Common Stock We may offer, issue and sell shares of our common stock from time to time. These securities may be offered together or separately and in one or more series, if any, in amounts, at prices and on other terms to be determined at the time of the offering and described in an accompanying prospectus supplement. You should read this prospectus and any prospectus supplement carefully before you invest. Our common stock is listed on Nasdaq under the symbol “BBBY.” We may offer and sell these securities through one or more underwriters, dealers or agents, through underwriting syndicates managed or co-managed by one or more underwriters, or directly to purchasers, on a continuous or delayed basis. The prospectus supplement for each offering of securities will describe in detail the plan of distribution for that offering. Investing in the manner set forth offered securities involves risks. You should carefully read and consider the information in this prospectus, the applicable prospectus supplement and the risk factors described in any applicable prospectus supplement and/or in our periodic and other reports and other information that we file with the Securities and Exchange Commission before investing in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus or any applicable prospectus supplement. Any representation to the contrary is a criminal offense. Prospectus dated August 31, 2022 TABLE OF CONTENTS ABOUT THIS PROSPECTUS 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 BED BATH & BEYOND INC. 4 RISK FACTORS 5 USE OF PROCEEDS 6 DESCRIPTION OF COMMON STOCK 7 PLAN OF DISTRIBUTION 9 LEGAL MATTERS 11 EXPERTS 11 WHERE YOU CAN FIND MORE INFORMATION, INCORPORATION BY REFERENCE 11 We are responsible for the information contained and incorporated by reference in this prospectus. We have not authorized anyone to give you any other information, and we take no responsibility for any other information that others may give you. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in this prospectus or any prospectus supplement is accurate as of any date other than the date of the document containing the information. ABOUT THIS PROSPECTUS This prospectus is part of an automatic shelf registration statement that we filed with the Securities and Exchange Commission, or the SEC, for the delayed offering and sale of securities pursuant to Rule 415 under the heading Securities Act of 1933, as amended, or the Securities Act. Under this shelf process, we may periodically sell the securities described in this prospectus in one or more offerings. This prospectus provides a general description of our common stock that we may offer. Each time we offer securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the registered securities to which they relate, and this prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom, it is unlawful to make such an offer or solicitation. You should not assume that the information contained in this prospectus and any accompanying prospectus supplement is correct on any date after the respective dates of the prospectus and such prospectus supplement or supplements, as applicable, even though this prospectus and such prospectus supplement or supplements are delivered or securities are sold pursuant to the prospectus and such prospectus supplement or supplements at a later date. Since the respective dates of the prospectus contained in this registration statement and any accompanying prospectus supplement, our business, financial condition, results of operations and prospects may have changed. The prospectus supplement may also add, update or change information, including information about us, contained in this prospectus. Therefore, before making your investment decision, you should carefully read: • this prospectus; • any applicable prospectus supplement, which (1) explains the specific terms of the securities being offered and (2) updates and changes information in this prospectus; and • the documents referred to in “Additional Where You Can Find More Information” in this prospectus for information about us, including our financial statements. References to “we,” above. Up “us,” “our” and the “Company” and “Bed Bath & Beyond” are references to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTBed Bath & Beyond Inc. and its consolidated subsidiaries, unless it is clear from the context that we mean only Bed Bath & Beyond Inc..

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectusprospectus supplement, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information documents incorporated by reference is an into this prospectus supplement contain important part of this prospectusinformation that you should read about us. The information following documents are incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in into this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162018, filed with the SEC on March 822, 20172019, including the information incorporated by reference into our Annual Report on Form 10-K from our definitive proxy statement for the 2019 Annual Meeting of Stockholders; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters period ended March 31, 20172019, filed with the SEC on May 910, 2017, 2019; • our Quarterly Report on Form 10-Q for the period ended June 30, 20172019, filed with the SEC on August 912, 2017 and September 30, 2017, 2019; • our Current Report on Form 8-K as filed with the SEC on November 8June 3, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● 2019 and our Current Reports Report on Form 8-K reporting pursuant to Items 5.02 and 9.01 of Form 8-K filed with the SEC on February 28August 5, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2019; and ● • the description of our common stock contained in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14September 26, 20152016, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All ; and • all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination or completion of the offering of securities under this prospectus supplement shall be deemed to be incorporated by reference in this prospectus supplement and to be a part hereof from the date of filing such reports and other documents. We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTAct

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The following documents filed by us with the SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information are incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 20162017, filed with the SEC on March 819, 20172018; ● our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 2017, 2018 filed with the SEC on May 910, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172018; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports Report on Form 8-K K, filed with the SEC on February 2813, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2018; and ● the The description of our common stock contained in our the Registration Statement on Form 8-AA filed pursuant to Section 12(b) of the Exchange Act on March 21, filed on April 14, 20152000, including any amendments thereto amendment or reports report filed with the SEC for the purposes purpose of updating this description. All reports and other We also incorporate by reference all documents that we file with pursuant to Section 13(a), 13(c), 14 or 15 of the SEC under Sections Exchange Act (other than any portions of filings that are furnished rather than filed pursuant to Items 2.02 and 7.01 of a Current Report on Form 8-K) after the date of the initial registration statement of which this prospectus is a part and prior to effectiveness of such registration statement. All documents we file in the future pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before and prior to the termination of the offering are also incorporated by reference and are an important part of the securities hereunder will also be considered this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference into herein shall be deemed to be modified or superseded for the purposes of this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” registration statement to the SEC will not extent that a statement contained herein or in any other subsequently filed document which also is or deemed to be considered incorporated by reference into herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectusregistration statement. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectus, upon written or oral requestprospectus is delivered, a copy of any or all of the preceding documents information that are has been incorporated by reference (other than exhibits, unless in the exhibits are specifically incorporated by reference into these documents)prospectus but not delivered with the prospectus. You may request a copy of these materials filings, excluding the exhibits to such filings which we have not specifically incorporated by reference in such filings, at no cost, by writing to or calling us at: ImageWare Systems, Inc. Attn: Corporate Secretary 00000 Xxxxxx Xxxxxxxx Xxxx, Suite 310 San Diego, California 92127 (000) 000-0000 This prospectus is part of a registration statement we filed with the manner set forth under SEC. You should only rely on the heading “Additional Information,” aboveinformation or representations contained in this prospectus and any accompanying prospectus supplement. Up We have not authorized anyone to $150,000,000 provide information other than that provided in this prospectus and any accompanying prospectus supplement. We are not making an offer of the securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or any accompanying prospectus supplement is accurate as of any date other than the date on the front of the document. T able of Contents PROSPECTUS 10,000,000 Shares of Common Stock PROSPECTUS SUPPLEMENTStock

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” into this prospectus the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated we incorporate by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in some of this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including filings made after the date of the initial registration statement, until we sell all of the shares covered by this prospectus or the sale of shares by us pursuant to this prospectus is terminated. In no event, however, will any of the information that we have previously furnish to, pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K (including exhibits related thereto) or other applicable SEC rules, rather than file with, the SEC be incorporated by reference or otherwise be included herein, unless such information is expressly incorporated herein by a reference in such furnished Current Report on Form 8-K or other furnished document. The documents we incorporate by reference are: • our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC: ● SEC on March 23, 2015; • our Annual Report Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015 and June 30, 2015 filed with the SEC on May 14, 2015 and August 14, 2015, respectively; • our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 17, 2015 (excluding those portions that are not incorporated by reference into our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 20172014); ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28January 2, 20172015, January 13, 2015, January 15, 2015, January 20, 2015, January 22, 2015, March 302, 20172015, March 13, 2015, March 17, 2015, March 19, 2015, May 2613, 20172015, June 9, 2015, and August 2211, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2015; and ● • the description of our common stock contained in our Registration Statement registration statement on Form 8-AA (File No. 001-36332) filed under the Exchange Act on March 4, filed on April 14, 20152014, including any amendments thereto amendment or reports filed for the purposes purpose of updating this descriptionsuch descriptions. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 Any statement contained in a document incorporated or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered deemed to be incorporated by reference into this prospectus from the date will be deemed to be modified or superseded for purposes of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” this prospectus to the SEC will not extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be considered incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We undertake to will provide without charge to each person (including any beneficial owner) who receives to whom a copy of this prospectus, upon written or oral request, prospectus is delivered a copy of all of the preceding documents information that are has been incorporated by reference (other than exhibits, unless in this prospectus but not delivered with the exhibits are specifically incorporated by reference into these documents)prospectus. You may obtain copies of these filings, at no cost, through the “Investor Relations” section of our website (xxx.xxxxxxx.xxx) and you may request a copy of these materials in filings (other than an exhibit to any filing unless we have specifically incorporated that exhibit by reference into the manner set forth under filing), at no cost, by writing or telephoning us at the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTfollowing address: 000 Xxxxxxxx Xxxxxx, Suite 320 Lexington, MA 02421 (000) 000-0000 Information on, or that can be accessed through, our website is not incorporated into this prospectus or other securities filings and is not a part of these filings.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate documents listed below are incorporated by reference” information that we file with it reference into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Annual Report Our annual report on Form 10-K for the fiscal year ended December 31, 2016, 2019 filed with the SEC on March 827, 20172020; and ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports Our current report on Form 8-K filed with the SEC on January 29, 2020, January 31, 2020, February 2824, 20172020, March 4, 2020, March 13, 2020, March 30, 20172020, May 26April 20, 2017, August 2020 and April 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2020 (other than any portions thereof deemed current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and not filedexhibits that are related to such item); and ● the The description of our common stock contained in our Registration Statement on Form 8-AA (File No. 001-38418), filed under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) on April 14March 9, 20152018, including any amendments thereto subsequent amendment or reports report filed for the purposes purpose of updating this amending such description. ; and ● All reports and other documents that we file with the SEC under subsequently filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of the offering offering, other than information furnished pursuant to Items 2.02 and 7.01 of the securities hereunder will also Form 8-K and any related exhibits, shall be considered deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” prospectus. Any statement contained in a document incorporated or deemed to the SEC will not be considered incorporated by reference into in this prospectusprospectus is modified or superseded for purposes of the prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectus, upon written or oral requestprospectus is delivered, a copy of any or all of the preceding documents information that are has been incorporated by reference (in this prospectus but not delivered with the prospectus. We are an Exchange Act reporting company and are required to file periodic reports on Form 10-K and 10-Q and current reports on Form 8-K. The Commission maintains an internet website that contains reports, proxy and information statements, and other than exhibitsinformation regarding issuers that file electronically with the Commission, unless the exhibits are specifically incorporated by reference into these documents)including Cocrystal at xxx.xxx.xxx. You may request also access our Exchange Act reports and proxy statements free of charge at our website, xxx.xxxxxxxxxxxxxxx.xxx. You may obtain a copy of these materials in the manner set forth under the heading “Additional Information,” above. any of our filings, at no cost, by contacting us at: 00000 X. Xxxxx Xxxxxxx Xxxxxxx, XX 00000 (000) 000-0000 Up to $150,000,000 10,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT X.X. Xxxxxxxxxx & Co.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference much of the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information incorporated that we incorporate by reference is an important part of in this prospectus. The information incorporated by reference prospectus supplement and the accompanying prospectus is considered to be a part of this prospectus supplement and the accompanying prospectus, and information that . Because we file later are incorporating by reference future filings with the SEC will automatically update SEC, this prospectus supplement and the accompanying prospectus is continually updated and those future filings may modify or supersede some of the information contained included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement, the accompanying prospectus supplementor in any document previously incorporated by reference have been modified or superseded. We incorporate This prospectus supplement and the accompanying prospectus incorporates by reference the documents listed below that and any future filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: ● • our Annual Report on Form F orm 10-K for the fiscal year ended December 31, 2016, 2019 and filed with the SEC on March 810, 20172020; ● • our Quarterly Reports Report on Form F orm 10-Q for the fiscal quarters quarter ended March 31, 2017, 2020 and filed with the SEC on May 912, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Current Reports on Form 8-K filed with the SEC on February 28J anuary 27, 20172020, March 30M information in such reports is filed and not furnished; arch 17, 20172020, May 26A pril 24, 20172020 and M ay 20, August 2020, to the extent the • our D efinitive Proxy Statement filed with the SEC on April 22, 20172020, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished to the extent the information therein is filed and not filed)furnished; and ● • the description of our common stock contained which is registered under Section 12 of the Exchange Act, in our Registration Statement registration statement on Form F orm 8-A, filed with the SEC on April 1417, 20152018, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All We also incorporate by reference into this prospectus supplement and the accompanying prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement but before prior to the termination or completion of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documentsoffering. These documents include, and will supersede the information herein; providedwithout limitation, howeverAnnual Reports on Form 10-K, that all reportsQuarterly Reports on Form 10-Q, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectusCurrent Reports on Form 8-K, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)as well as proxy statements. You may request a copy of these materials filings, at no cost, by contacting us, either orally or in writing, at the following: Surface Oncology, Inc. 00 Xxxxxxxxx Xxxxxx, 0xx Xxxxx Xxxxxxxxx, Xxxxxxxxxxxxx 00000 (000) 000-0000 PROSPECTUS $180,000,0000 Common Stock Preferred Stock Debt Securities Warrants Units From time to time, we may offer up to $180,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions. This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. Our common stock is traded on the Nasdaq Global Market under the symbol “SURF.” On April 29, 2019, the last reported sale price of our common stock was $4.79 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. We may sell these securities directly to investors, through agents designated from time to time, or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any agents or underwriters are involved in the manner sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Additional InformationRisk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 8 of this prospectus. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is May 8, 2019. T able of Contents Page A BOUT THIS PROSPECTUS 1 S UMMARY 2 T HE SECURITIES WE MAY OFFER 7 R ISK FACTORS 8 S PECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 9 U SE OF PROCEEDS 11 D ESCRIPTION OF CAPITAL STOCK 12 D ESCRIPTION OF DEBT SECURITIES 17 D ESCRIPTION OF WARRANTS 24 D ESCRIPTION OF UNITS 25 P LAN OF DISTRIBUTION 28 L EGAL MATTERS 31 E XPERTS 31 W HERE YOU CAN FIND MORE INFORMATION 31 ABOUT THIS PROSPECTUS This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $180,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading “Incorporation of Certain Information by Reference,” abovebefore investing in any of the securities offered. Up to $150,000,000 Common Stock THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.”

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus supplement and the accompanying prospectus. The Information in this prospectus supplement supersedes information incorporated by reference is considered to be a part of this prospectus, and information that we file later filed with the SEC will automatically update and supersede information contained in prior to the date of this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 20172022; ● our Current Reports Report on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October January 24, 2017 and November 27, 2017 2022 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock stock, par value $0.0001 per share, contained in our Registration Statement on Form 8-A, A filed on April 14August 12, 20152013, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act Act, except as to any portion of any report or documents that is not deemed filed under such provisions, on or after the date of this prospectus but before supplement until the termination of this offering shall be deemed incorporated by reference in this prospectus supplement and the offering accompanying prospectus and to be a part of this prospectus supplement from the date of filing of those documents. We will furnish without charge to you, on written or oral request, a copy of any or all of the securities hereunder will documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents to Vyant Bio, Inc., 2370 1357 Route 70 West, Two Executive Campus, Suite 310, Cherry Hill, NJ 00000-0000; Telephone: (201) 000- 0000. Copies of the above reports may also be considered accessed from our website at xxx.xxxxxxxx.xxx. The information contained on, or that may be obtained from, our website is not, and shall not be deemed to be, a part of this prospectus supplement or the accompanying prospectus. We have authorized no one to provide you with any information that differs from that contained in this prospectus supplement, the accompanying prospectus or incorporated by reference herein or therein. Accordingly, you should not rely on any information that is not contained in this prospectus supplement or the accompanying prospectus or incorporated by reference herein or therein. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date of the front cover of this prospectus supplement. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus supplement will be deemed modified, superseded or replaced for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement modifies, supersedes or replaces such statement. PROSPECTUS Cancer Genetics, Inc. $100,000,000 Common Stock Preferred Stock Warrants Debt Securities Subscription Rights Units We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock, which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi) units. The debt securities may consist of debentures, notes, or other types of debt. The debt securities, preferred stock, warrants and subscription rights may be convertible into, or exercisable or exchangeable for, common or preferred stock or other securities of ours. The units may consist of any combination of the securities listed above. The aggregate public offering price of the securities that we may offer will not exceed $100,000,000. We will offer the securities in an amount and on terms that market conditions will determine at the time of the offering. Our common stock is listed on the Nasdaq Capital Market under the symbol “CGIX.” The last reported sale price for our common stock on June 25, 2020 as quoted on the Nasdaq Capital Market was $3.04 per share. You are urged to obtain current market quotations of our common stock. We have no preferred stock, warrants, debt securities, subscription rights or units listed on any market. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. Investing in our securities involves risk. You should carefully consider the risks that we refer you to under the section captioned “Risk Factors” in this prospectus on page 3 before buying our securities. Should we offer any of the securities described in this prospectus, we will provide you with the specific terms of the particular securities being offered in supplements to this prospectus. You should read this prospectus and any supplement, together with additional information described under the headings “Additional Information” and “Incorporation of Certain Information by Reference” carefully before you invest. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement. We may sell these securities directly to our stockholders or to other purchasers or through agents on our behalf or through underwriters or dealers as designated from time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement will provide the names of the agents or underwriters and any applicable fees, commissions or discounts. The aggregate market value of the shares of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is approximately $8,680,000, which was calculated based on 2,169,880 shares of our common stock outstanding and held by non-affiliates as of the date of this Prospectus and a price of $4.00 per share, the filing closing price of our common stock on the Nasdaq Capital Market on June 8, 2020. We have not sold any securities of the types listed above pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on, and includes the date of this Prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these reports securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is July 21, 2020. TABLE OF CONTENTS RISK FACTORS 3 ABOUT THIS PROSPECTUS 1 PROSPECTUS SUMMARY 2 USE OF PROCEEDS 5 FORWARD-LOOKING STATEMENTS 4 DESCRIPTION OF CAPITAL STOCK 6 THE SECURITIES WE MAY OFFER 6 DESCRIPTION OF DEBT SECURITIES 11 DESCRIPTION OF STOCK WARRANTS 10 DESCRIPTION OF UNITS 17 DESCRIPTION OF SUBSCRIPTION RIGHTS 16 PLAN OF DISTRIBUTION 19 FORMS OF SECURITIES 18 EXPERTS 24 LEGAL MATTERS 23 ADDITIONAL INFORMATION 26 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 25 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 27 Cancer Genetics, Inc. is referred to herein as “Cancer Genetics,” “the Company,” “we,” “us,” and documents, and will supersede “our,” unless the context indicates otherwise. You may only rely on the information herein; provided, however, that all reports, exhibits contained in this prospectus and other information the accompanying prospectus supplement or that we “furnish” have referred you to. We have not authorized anyone to provide you with different information. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities other than the SEC will securities offered by this prospectus and the prospectus supplement. This prospectus and any prospectus supplement do not be considered incorporated constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus or any prospectus supplement nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or such prospectus supplement or that the information contained by reference into to this prospectus or any prospectus supplement is correct as of any time after its date. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process. Under this shelf registration process, we may from time to time offer and sell, in one or more offerings, any or all of the securities described in this prospectus, separately or together, up to an aggregate offering price of $100,000,000. This prospectus provides you with a general description of our securities being offered. When we issue the securities being offered by this prospectus, we will provide a prospectus supplement (which term includes, as applicable, the at-the-market sale agreement prospectus filed with the registration statement of which this prospectus forms a part) that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in this prospectus. We undertake to provide without charge to each person (including You should read both this prospectus and any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth prospectus supplement together with additional information described under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTand “Incorporation of Certain Information by Reference.”

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference much of the information that we file with it into this prospectus, which means that we can them. This allows us to disclose important information to you by referring you to those publicly filed documents. The information incorporated that we incorporate by reference is an important part of in this prospectus. The information incorporated by reference prospectus supplement is considered to be a part of this prospectus supplement. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus, and information . This means that you must look at all of the SEC filings that we file later with incorporate by reference to determine if any of the SEC will automatically update and supersede information contained statements in this prospectus and supplement or in any accompanying document previously incorporated by reference have been modified or superseded. This prospectus supplement. We incorporate supplement incorporates by reference the documents listed below that (File No. 001-38161) and any future filings we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed: • Annual Report on Form 10-K for the year ended December 31, 2020 (including the information in Part III incorporated therein by reference from our Definitive Proxy Statement on Schedule 14A); • Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2021; • our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC onFebruary 19, 2021 (solely with respect to Item 5.02), March 18, 2021, May 21, 2021, and July 15, 2021 (solely with respect to Item 5.02); and • the description of our common stock contained in the Registration Statement onForm 8-A filed on July 20, 2017, including any amendment or report filed for the purpose of updating such description. We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus but before supplement is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities hereunder shares of our common stock made by this prospectus supplement and will also become a part of this prospectus supplement from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be considered deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference into to the extent that statements in the later filed document modify or replace such earlier statements. PROSPECTUS $200,000,000 CALYXT, INC. Common Stock Preferred Stock Warrants Subscription Rights Units Debt Securities We may offer and sell from time to time in one or more offerings shares of our common stock, shares of our preferred stock, warrants, subscription rights, units or debt securities for an aggregate offering price of $200,000,000. Any of these securities may be offered separately or in combination at prices and on other terms to be determined at the time of the offering. Each time we offer any securities pursuant to this prospectus, we will provide a prospectus supplement that will provide the specific terms of the securities to the extent those terms are not described in this prospectus or are different from the date terms described in this prospectus. The prospectus supplements may also add to, update or change information contained in this prospectus. In addition, we may supplement, update or change any of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other contained in this prospectus by incorporating information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplements and any documents incorporated by reference carefully before you invest. We undertake may offer these securities directly to investors, through agents, underwriters or dealers, or through a combination of these methods. Each applicable prospectus supplement will provide without charge the terms of the plan of distribution relating to each person the specific offering. If any agents, dealers or underwriters are involved in the sale of any securities, the applicable prospectus supplement will set forth their names and any applicable commissions or discounts. Our common stock is listed on the Nasdaq Global Market (including “Nasdaq”) under the symbol “CLXT.” On September 13, 2019, the closing sale price of our common stock on Nasdaq was $7.71 per share. Investing in our securities involves risks. See “Risk Factors” on page 4 and any beneficial owner) who receives risk factors included in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a copy discussion of the factors you should carefully consider before investing in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus is September 16, upon written or oral request2019. TABLE OF CONTENTS ABOUT THIS PROSPECTUS ii SUMMARY 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 RISK FACTORS 4 USE OF PROCEEDS 5 DESCRIPTION OF CAPITAL STOCK 6 DESCRIPTION OF WARRANTS 13 DESCRIPTION OF SUBSCRIPTION RIGHTS 14 DESCRIPTION OF UNITS 15 DESCRIPTION OF DEBT SECURITIES 16 PLAN OF DISTRIBUTION 23 VALIDITY OF THE SECURITIES 25 EXPERTS 25 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 26 WHERE YOU CAN FIND ADDITIONAL INFORMATION 26 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the “SEC”) utilizing a “shelf” registration process. Under this shelf registration process, a copy of all we may offer and sell from time to time any combination of the preceding securities described in this prospectus in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering. This prospectus and the documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated we incorporate by reference into these documents)this prospectus provide you with a general description of the securities under this shelf registration statement. You In connection with a specific offering, we may request provide a copy prospectus supplement and may also provide you with a free writing prospectus that will contain specific information about the terms of these materials that offering. The prospectus supplement or free writing prospectus, if any, may also add to, update or change information contained in this prospectus. Before purchasing any securities, you should carefully read both this prospectus, any applicable accompanying prospectus supplement and any free writing prospectus prepared by or on behalf of us, together with the manner set forth additional information described under the heading “Where You Can Find Additional Information” in this prospectus. We have not authorized any other person to provide you with any information different than that contained or incorporated by reference in this prospectus and any applicable accompanying prospectus supplement or free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it as having been authorized by us. We are not making offers to sell the securities and are not soliciting offers to buy the securities in any jurisdiction where an offer or solicitation is not permitted. The information in this prospectus is accurate only as of the date on the front cover. You should not assume that the information contained in this prospectus, including any information incorporated in this prospectus by reference, any applicable accompanying prospectus supplement or any free writing prospectus prepared by us, is accurate as of any date other than the date on the front of these documents. Our business, financial condition, results of operations and prospects may have changed since such date. Neither the delivery of this prospectus nor any sale made under it implies that there has been no change in our affairs or that the information in this prospectus is correct as of any date after the date of this prospectus. We encourage you to consult your own counsel, accountant and other advisors for legal, tax, business, financial and related advice regarding an investment in our securities. When we use the terms “we,” above“us,” the “Company,” or “our” in this report, unless the context otherwise requires, we are referring to Calyxt, Inc. When we use the term “Cellectis” we are referring to Cellectis S.A., our majority stockholder. Up We own the name and trademark, Calyxt® and Calyno™; we also own or license other trademarks, trade names and service marks of Calyxt appearing in this this prospectus and any prospectus supplement or free writing prospectus. The name and trademark, “Cellectis®” and “TALEN®”, and other trademarks, trade names and service marks of Cellectis appearing in this prospectus and any prospectus supplement or free writing prospectus are the property of Cellectis. This prospectus, any prospectus supplement and any free writing prospectus may also contain additional trade names, trademarks and service marks belonging to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTother companies. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. SUMMARY Our Company We are a healthy food ingredient company. We leverage proprietary intellectual property, our technical expertise, and anend-to-end supply chain toward our mission of “Making the Food You Love a Healthier Choice™”. Using our proprietary technologies and expertise, including XXXXX xxxx-editing technology exclusively licensed to us in the field of agriculture, we develop food crops with targeted traits quickly and more cost effectively than traditional methods. Our technologies enable precise cuts to DNA in a single plant cell. This allows us to use the plant’s natural repair machinery to make our desired genome edit and regenerate the single cell into a full plant that includes this gene edit. We believe that we can identify a consumer need and develop a product from “concept to fork” in cycles as short as six years by utilizing these proprietary technologies. We believe that we are well-positioned to address consumer preferences that are evolving to demand healthier, more nutritionally rich foods. To bring our consumer-centric products to the marketplace, we intend to repurpose and leverage existing supply chain capacity by contracting, tolling or partnering with players in the existing supply chain, such as seed production companies, seed distributors, farmers, crushers, millers, and refiners. We expect this will allow us to apply our resources to maximizing innovation and product development while minimizing our capital expenditures and overhead. We intend to strategically out-license our intellectual property to maximize our market opportunity. Our first commercial products are oil and meal derived from a High Oleic Soybean designed to produce a healthier oil that has increased heat stability with zero grams of trans fat per serving. We completed our first sales of our High Oleic Soybean Oil and High Oleic Soybean Meal in the first quarter of 2019. Among our other product candidates are other soybean products and a High Fiber Wheat. Our current commercial focus is North America. This may expand over time to other geographies, subject to customer demand and regulatory requirements, among other factors. We also intend to explore the ability to add value through our existing product candidates once they are commercialized by combining traits in the same crop, which may allow us to deliver products with additional benefits without adding significant cost. Relationship with Cellectis Prior to our initial public offering (“IPO”) on July 25, 2017, we were a wholly-owned subsidiary of Cellectis S.A. As of June 30, 2019, Cellectis owned approximately 69.1% of our outstanding common stock. In connection with the IPO, we and Xxxxxxxxx entered into certain agreements that relate to our relationship with Cellectis and provide a framework for our ongoing relationship with Cellectis. These agreements include a management services agreement, pursuant to which Cellectis provides certain support functions on a centralized basis and allocates a portion of the expense to us; a Stockholders Agreement, (as defined below), which provides Cellectis with certain contractual rights as long as it maintains threshold beneficial ownership levels in our shares; and a license agreement, pursuant to which we hold an exclusive, worldwide license in plants to key intellectual property owned by Cellectis. Corporate Information Calyxt was incorporated in the State of Delaware in 2010. Our corporate headquarters is located at 0000 Xxxxx Xxxxx Xxxx, Xxxxxxxxx, Xxxxxxxxx 00000 and our phone number is (000) 000-0000. Our filings with the SEC are posted on out corporate website at xxx.xxxxxx.xxx. The information contained in, or accessible through, our corporate website does not constitute part of this prospectus. Our common stock is listed on the Nasdaq Global Market under the symbol “CLXT.”

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by referenceincorporate” into this prospectus information that we file with it into this prospectus, which the SEC in other documents. This means that we can disclose important information to you by referring you to those documentsother documents that contain that information. The Any information incorporated that we incorporate by reference into this prospectus is an important considered part of this prospectus. The Information contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is considered inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. For more information, and information that we file later with the SEC will automatically update and supersede information contained in see “About this prospectus and any accompanying prospectus supplement. Prospectus.” We incorporate by reference reference, as of their respective dates of filing, the documents listed below that we have previously filed with the SECSEC and any additional documents that we may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including any documents filed after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been “furnished” and not “filed” in accordance with SEC rules: ● · our Annual Report on Form 10-K for the fiscal year ended December 31, 20162017, as filed with the SEC on March 81, 20172018; ● · our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 20172018 and June 30, 2018, as filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 20172018 and August 13, 2018, respectively; ● · our Current Reports on Form 8-K as filed with the SEC on February 28each of March 12, 2017, March 30, 2017, May 26, 20172018, August 229, 20172018 and September 11, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2018; and ● · the description of our common stock contained in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14February 3, 2015, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We hereby undertake to provide without charge to each person (person, including any beneficial owner) who receives a copy of , to whom this prospectusprospectus is delivered, upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (into this prospectus, but not delivered with the prospectus, other than exhibits, exhibits to such documents unless the such exhibits are specifically incorporated by reference into these documents)this prospectus. To request such materials, please contact Xx. Xxxxxx Xxxxxxxxx, our Corporate Secretary, at c/o Corporate Secretary, VolitionRx Limited, 0 Xxxxxx Xxxx, #00-00 Xxxx Xxxxxx, Singapore, 228208, by telephone at +0 (000) 000-0000 or by email at xxxxxx@xxxxxxxxxx.xxx. These documents are also available free of charge through the investors section on our website at xxxx://xxx.xxxxxxxxxx.xxx as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. You should rely only on the information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may request provide to you. The information contained in this prospectus, in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and prospects may have changed since those respective dates. WHERE YOU CAN FIND MORE INFORMATION We have filed a registration statement on Form S-3 with the SEC relating to the securities offered by this prospectus. As permitted by the SEC rules and regulations, this prospectus and any accompanying prospectus supplement that we may file, which form a part of the registration statement, do not contain all of the information set forth in the registration statement and the exhibits and schedules thereto. Statements contained in this prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each instance reference is made to the copy of such contract or other document filed as an exhibit to the registration statement, each such statement being qualified in all respects by such reference. For further information with respect to us and the common stock, the warrants and the units offered hereby, reference is made to such registration statement, exhibits and schedules. We are subject to the information and periodic reporting requirements of the Exchange Act, and in accordance therewith file periodic reports, current reports, proxy statements and other information with the SEC. Such periodic reports, current reports, proxy statements, other information and a copy of the registration statement on Form S-3 may be inspected by anyone without charge and copies of these materials in may be obtained upon the manner set forth under payment of the heading “Additional Information,” abovefees prescribed by the SEC, at the Public Reference Room maintained by the SEC at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 0-000-XXX-0000. The registration statement on Form S-3 and the periodic reports, current reports, proxy statements and other information filed by us are also available through the SEC’s website at xxxx://xxx.xxx.xxx. Up to $150,000,000 25,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Cantor Xxxxxxxxxxx & Co.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference much of the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information incorporated that we incorporate by reference in this prospectus is an important considered to be part of this prospectus. The Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this have been modified or superseded. This prospectus and any accompanying prospectus supplement. We incorporate incorporates by reference the documents listed below that and any future filings we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement until the offering of the securities under the registration statement is terminated or completed: • our Annual Report on F orm 10-K for the fiscal year ended December 31, 2018 and filed with the SEC on March 7, 2019; • Current Reports on Form 8-K filed with the SEC on F ebruary 13, 2019 and F ebruary 4, 2019 to the extent the information in such reports is filed and not furnished; • our D efinitive Proxy Statement filed with the SEC on April 19, 2019, to the extent the information therein is filed and not furnished; and • the description of our common stock which is registered under Section 12 of the Exchange Act, in our registration statement on F orm 8-A, filed with the SEC on April 17, 2018, including any amendments or reports filed for the purpose of updating such description. We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, and (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documentsoffering. These documents include, and will supersede the information herein; providedwithout limitation, howeverAnnual Reports on Form 10-K, that all reportsQuarterly Reports on Form 10-Q, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectusCurrent Reports on Form 8-K, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)as well as proxy statements. You may request a copy of these materials filings, at no cost, by contacting us, either orally or in writing, at the manner set forth under the heading “Additional Information,” above. Up to following: Surface Oncology, Inc. 00 Xxxxxxxxx Xxxxxx, 0xx Xxxxx Xxxxxxxxx, Xxxxxxxxxxxxx 00000 (000) 000-0000 32 $150,000,000 50,000,000 Common Stock PROSPECTUS SUPPLEMENT

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-38052. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162017, filed with the SEC on March 89, 20172018; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarterly period ended March 31, 20172018, filed with the SEC on May 911, 2017, June 30, 2017, filed with 2018; • the SEC information specifically incorporated by reference into our Annual Report on August 9Form 10-K for the fiscal year ended December 31, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● from our Proxy Statement definitive proxy statement on Schedule 14A (other than information furnished, rather than filed) filed with the SEC on April 1030, 20172018; ● • our Current Reports on Form 8-K (other than information furnished, rather than filed) filed with the SEC on January 12, 2018, February 2813, 20172018, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October April 19, 20172018 and May 23, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2018; and ● • the description of our common stock contained stock, which is registered under Section 12 of the Exchange Act, in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 144, 20152017, including any all amendments thereto or reports filed for the purposes purpose of updating this such description. All reports We also incorporate by reference into this prospectus all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits which are specifically incorporated by reference into these such documents). You may request should direct any requests for documents by writing us at 0000 Xxxxxx Xxxx Xxxxxx, Xxxxx 000, Xxx Xxxxx, Xxxxxxxxxx 00000, Attn: Corporate Secretary or telephoning us at (000) 000-0000. Any statement contained herein or in a copy document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of these materials the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTstatement.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The ‌‌ This Prospectus Supplement is part of the Fund’s registration statement on file with the SEC. Pursuant to rules issued by the SEC allows us as a part of the Securities Offering Reform for Closed-End Investment Companies, the Fund is permitted to “incorporate by reference” information that we file filed with it into this prospectusthe SEC, which means that we the Fund can disclose important information to you shareholders by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information Information incorporated by reference is considered to be a part of this prospectusProspectus Supplement, and later information that we file later the Fund files with the SEC will automatically update and supersede information contained in this prospectus information. The documents listed below, and any accompanying prospectus supplement. We incorporate by reference the reports and other documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, subsequently filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for pursuant to Section 30(b)(2) of the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 1940 Act and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before Act, prior to the termination of the this offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus Prospectus Supplement and deemed to be part of this Prospectus Supplement from the date of the filing of these such reports and documents:  the Fund’s Statement of Additional Information, dated September 30, 2020, filed with this Prospectus Supplement and will supersede the accompanying Prospectus  the Fund’s Semi-Annual Report on Form N-CSR, filed on May 29, 2020;  the Fund’s Proxy Statement on Form DEF 14A, filed on January 10, 2020;  the Fund’s Annual Report on Form N-CSR, filed on December 3, 2019;  the Fund’s description of Common Shares on Form 8-A, filed on April 12, 2013. The Fund’s periodic reports filed pursuant to Section 30(b)(2) of the 1940 Act and Sections 13 or 15(d) of the Exchange Act, as well as this Prospectus Supplement are available on the Fund’s website at xxx.xxxxxxxxxxxxxxx.xxx. Other information herein; provided, however, that all reports, exhibits and other information that we “furnish” to contained on the SEC will website is not be considered incorporated by reference into this prospectusProspectus Supplement and the accompanying Prospectus and you should not consider information contained on the website to be part of this Prospectus Supplement and the accompanying Prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives You may also request a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference these filings (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents) and any other information incorporated by reference into this Prospectus Supplement, the Prospectus or the SAI upon written or oral request at no cost by contacting your financial intermediary if you invest through a financial intermediary. If you are a direct investor, you may call 877- DLINE11 (000-000-0000), send an email request to xxxxxxxx@xxxxxxxxxx.xxx or write to the Fund at 000 Xxxxx Xxxxx Xxxxxx, Xxxxx 0000, Xxx Xxxxxxx, Xxxxxxxxxx 00000. You may request In addition, the SEC maintains a copy of website at xxx.xxx.xxx that contains these materials in reports, proxy and information statements, and other information, including filings on Form N-PORT and N-CEN, regarding issuers that file electronically with the manner set forth under SEC, including the heading “Additional Information,” aboveFund. Up to $150,000,000 500,000,000 DoubleLine Income Solutions Fund Common Stock PROSPECTUS SUPPLEMENTShares of Beneficial Interest Prospectus Supplement September 30, 2020

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference the information that and reports we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those these documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectusprospectus supplement, and information that we file later after the date hereof with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementalready incorporated by reference. We incorporate are incorporating by reference the documents listed below that we have previously below: • Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC: ● SEC on March 26, 2021; • The information specifically incorporated by reference in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 13, 2020, from the Company’s Definitive Proxy Statement on Schedule 14A relating to the Company’s 2020 Annual Meeting of Stockholders, which was filed with the SEC on April 10, 2020; • Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on January 4, 2021 and January 20, 2021; and • The description of our common stock contained in Exhibit 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 20162020, as filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 20152021, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by reference in this prospectus supplement and to be a part of this prospectus supplement from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed “filed” under such provisions on or after the date of this prospectus but before supplement, until the termination earlier of the offering date on which: (1) all of the securities registered hereunder have been sold; or (2) the registration statement of which this prospectus supplement is a part has been withdrawn. Under no circumstances will also any information filed under current items 2.02 or 7.01 of Form 8-K be considered to be deemed incorporated herein by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” unless such Form 8-K expressly provides to the SEC contrary. Upon written or oral request, we will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives to whom a copy of this prospectus, upon written or oral request, the prospectus supplement is delivered a copy of all of the preceding documents that are incorporated by reference herein (other than exhibits, exhibits to such documents unless the such exhibits are specifically incorporated by reference into these documentsherein). You may request a copy of these materials in filings, at no cost, by writing, calling or emailing us at the manner contact information set forth below. We have authorized no one to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date of the front cover of this prospectus supplement. Viridian Therapeutics, Inc. 0000 Xxxxxxx Xxxx Boulder, CO 80301 (000) 000-0000 PROSPECTUS $175,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer and sell up to $175,000,000 of any combination of the securities described in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, exchange or exercise of any securities registered pursuant to this prospectus. This prospectus provides a general description of securities we may offer. Each time we offer and sell securities, we will provide the specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities being offered. This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. Our common stock is listed on The Nasdaq Capital Market under the symbol “MGEN.” On March 25, 2020, the last reported sale price of our common stock on The Nasdaq Capital Market was $0.4832 per share. Any applicable prospectus supplement will contain information, as applicable, as to other listings, if any, on The Nasdaq Capital Market or other securities exchange of the securities covered by the prospectus supplement. We may sell these securities to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the discussion under the heading “Additional Plan of Distribution” in this prospectus and in any applicable prospectus supplement. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” contained in this prospectus, in any applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this Prospectus is April 14, 2020. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process. Under this shelf registration statement, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $175,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also add, update or change in a prospectus supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. This prospectus, together with any applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and any applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and any applicable prospectus supplement and any related free writing prospectus, together with the additional information described under “Where You Can Find More Information,” abovebefore buying any of the securities being offered. Up to $150,000,000 Common Stock THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell or seeking an offer to buy securities under this prospectus or any applicable prospectus supplement and any related free writing prospectus in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any accompanying prospectus supplement, the documents incorporated by reference in this prospectus, any accompanying prospectus supplement and in any free writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, any accompanying prospectus supplement, the documents incorporated by reference in this prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.” This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, industry, statistical and market data from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified statistical, market and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit or incorporated by reference to the registration statement of which this prospectus forms a part were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information into this prospectus from other documents that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus. The Information in this prospectus supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectus, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementprospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have previously filed with the SEC: ● SEC (Commission File No. 001-40672): • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC on March 831, 20172022; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172022 filed with the SEC on May 11, 2022; • the information specifically incorporated by reference in our Annual Report on Form 10-K for the year ended December 31, 2021, from our definitive proxy statement relating to our 2022 annual meeting of stockholders, filed with the SEC on May 9April 13, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172022; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28January 5, 20172022, March 3023, 2017, 2022 and May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● • the description of our Class A common stock contained stock, which is registered under the Exchange Act in our Registration Statement the registration statement on Form 8-AA12B, filed with the SEC on April 14July 26, 20152021, including any amendments thereto or reports filed for the purposes of updating this description, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 of our Annual Report on Form 10-K for the year ended December 31, 2021. All filings filed by us pursuant to the Exchange Act after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus. We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act Act, including those made after the date of the initial filing of the registration statement of which this prospectus but before is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities hereunder made by this prospectus and will also be considered to be incorporated by reference into become a part of this prospectus from the date of that such documents are filed with the filing of these reports SEC. Information in such future filings updates and documents, and will supersede supplements the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into provided in this prospectus. We undertake Any statements in any such future filings will automatically be deemed to provide without charge modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are be incorporated herein by reference (other than exhibits, unless to the exhibits are specifically incorporated by reference into these documents)extent that statements in the later filed document modify or replace such earlier statements. You may can request a copy of these materials in filings, at no cost, by writing or telephoning us at the manner set forth under the heading “Additional Information,” above. following address or telephone number: Rani Therapeutics Holdings, Inc. 0000 Xxxxxxxx Xxxxxx Xxx Xxxx, Xxxxxxxxxx 00000 Attn: Secretary (000) 000-0000 Up to $150,000,000 Class A Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Cantor X.X. Xxxxxxxxxx & Co.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documentsanother document that we have filed separately with the SEC. The Any information incorporated by reference is an important part of this prospectus. The information incorporated that we incorporate by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. .We hereby incorporate by reference the following information or documents listed below that we have previously filed with into this prospectus supplement and the SECaccompanying prospectus: ● our Annual Report · Our annual report on Form 10-K for the fiscal year ended December 31April 30, 20162022 filed onJuly 29, 2022 and our annual report on Form 10-K for the year ended April 30, 2021 filed with the SEC on March 8July 13, 20172021, as amended; ● our Quarterly Reports · Our quarterly report on Form 10-Q for the fiscal quarters quarter ended March July 31, 20172021, filed with onSeptember 14, 2021, our quarterly report on Form 10-Q for the SEC on May 9quarter ended October 31, 2017, June 30, 20172021, filed with on December 14, 2021, and our quarterly report on Form 10-Q for the SEC on August 9quarter ended January 31, 2017 and September 30, 20172022, filed with the SEC on November 8onMarch 15, 20172022; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports · Our current reports on Form 8-K filed with the SEC on February 28June 1, 20172022; June 14, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● the July 12, 2022; · The description of our common stock contained in our Registration Statement registration statement on Form 8-AA filed with the SEC onJuly 31, filed on April 142017, 2015, including as updated by any amendments thereto or and reports filed for the purposes purpose of updating such description; and · All documents subsequently filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) prior to the termination of the offering, other than information furnished pursuant to Items 2.02 and 7.01 of Form 8-K and any related exhibits, shall be deemed to be incorporated by reference into the prospectus. Any information in any of the foregoing documents will automatically be deemed to be modified or superseded to the extent that information in this descriptionprospectus supplement or the accompanying prospectus or in a later filed document that is incorporated or deemed to be incorporated herein by reference modifies or replaces such information. All reports We also incorporate by reference any future filings (excluding information furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering Act, until we sell all of the securities hereunder offered by this prospectus supplement. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will also automatically be considered deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. Upon written or oral request, we will provide to you, without charge, a copy of any or all of the documents that are incorporated by reference into this prospectus from supplement and the date of accompanying prospectus but not delivered with the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the including exhibits which are specifically incorporated by reference into these such documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTRequests should be directed to: 000 Xxxxx Xxxxxx, Xxxxx 000 Xxx Xxxx, Xxx Xxxx 00000 (646) 448-5144 Attention: Corporate Secretary

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows SEC’s rules allow us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered deemed to be a part of this prospectus, and subsequent information that we file later with the SEC will automatically update and supersede previously filed information as applicable. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement. Since information that we later file with the SEC will update and supersede previously incorporated information, you should look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or any accompanying prospectus supplementsupplement or in any documents previously incorporated by reference have been modified or superseded. We incorporate by reference the into this prospectus our documents listed below that we have previously filed and any future filings made by us with the SEC: ● SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, between the date of this prospectus and the termination of the offering of the securities described in this prospectus (in each case, other than information deemed furnished and not filed in accordance with SEC rules, including pursuant to Items 2.02 and 7.01 of Form 8-K or corresponding information furnished under Item 9.01 or included in a furnished exhibit, except as stated specifically below): · our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 816, 20172020; ● · our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172020, filed with the SEC on May 915, 2017, 2020; · our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 20172020, filed with the SEC on August 914, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● · our Current Reports on Form 8-K K, filed with the SEC on February 28January 31, 20172020; March 20, 2020; March 23, 2020; April 6, 2020; April 29, 2020; May 7, 2020; June 4, 2020; July 6, 2020; July 10, 2020; July 30, 20172020; August 3, May 262020; September 4, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● the September 11, 2020; and · The description of our common stock contained in Exhibit 4.5 to our Registration Statement Annual Report on Form 810-AK for the year ended December 31, 2019, filed with the SEC on April 14March 16, 20152020, including any amendments thereto other amendment or reports filed for the purposes purpose of updating this such description. All In addition, all reports and other documents that we may file with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement of which this prospectus but before the termination forms a part, and prior to effectiveness of the offering of the securities hereunder will also such registration statement, shall be considered deemed to be incorporated by reference into this prospectus from the date of the filing prospectus. The file number for all such filings is 001-35798. You may request a free copy of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference filings (other than exhibits, an exhibit to a filing unless the exhibits are that exhibit is specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTthat filing) by writing or telephoning us as follows: Humanigen, Inc. Attention: Corporate Secretary 000 Xxxxxxx Xxxxxxxxx, Xxxxx 000 Burlingame, CA 94010 (000) 000-0000

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The ‌ This Prospectus Supplement is part of the Fund’s registration statement on file with the SEC. Pursuant to rules issued by the SEC allows us as a part of the Securities Offering Reform for Closed-End Investment Companies, the Fund is permitted to “incorporate by reference” information that we file filed with it into this prospectusthe SEC, which means that we the Fund can disclose important information to you shareholders by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information Information incorporated by reference is considered to be a part of this prospectusProspectus Supplement, and later information that we file later the Fund files with the SEC will automatically update and supersede information contained in this prospectus information. The documents listed below, and any accompanying prospectus supplement. We incorporate by reference the reports and other documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, subsequently filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for pursuant to Section 30(b)(2) of the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 1940 Act and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before Act, prior to the termination of the this offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus Prospectus Supplement and deemed to be part of this Prospectus Supplement from the date of the filing of these such reports and documents:  the Fund’s Statement of Additional Information, dated September 30, 2020, filed with this Prospectus Supplement and will supersede the accompanying Prospectus  the Fund’s Semi-Annual Report on Form N-CSR, filed on May 29, 2020;  the Fund’s Proxy Statement on Form DEF 14A, filed on January 10, 2020;  the Fund’s Annual Report on Form N-CSR, filed on December 3, 2019;  the Fund’s description of Common Shares on Form 8-A, filed on January 18, 2012. The Fund’s periodic reports filed pursuant to Section 30(b)(2) of the 1940 Act and Sections 13 or 15(d) of the Exchange Act, as well as this Prospectus Supplement are available on the Fund’s website at xxx.xxxxxxxxxxxxxxx.xxx. Other information herein; provided, however, that all reports, exhibits and other information that we “furnish” to contained on the SEC will website is not be considered incorporated by reference into this prospectusProspectus Supplement and the accompanying Prospectus and you should not consider information contained on the website to be part of this Prospectus Supplement and the accompanying Prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives You may also request a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference these filings (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents) and any other information incorporated by reference into this Prospectus Supplement, the Prospectus or the SAI upon written or oral request at no cost by contacting your financial intermediary if you invest through a financial intermediary. If you are a direct investor, you may call 877- DLINE11 (000-000-0000), send an email request to xxxxxxxx@xxxxxxxxxx.xxx or write to the Fund at 000 Xxxxx Xxxxx Xxxxxx, Xxxxx 0000, Xxx Xxxxxxx, Xxxxxxxxxx 00000. You may request In addition, the SEC maintains a copy of website at xxx.xxx.xxx that contains these materials in reports, proxy and information statements, and other information, including filings on Form N-PORT and N-CEN, regarding issuers that file electronically with the manner set forth under SEC, including the heading “Additional Information,” aboveFund. Up to $150,000,000 100,000,000 DoubleLine Opportunistic Credit Fund Common Stock PROSPECTUS SUPPLEMENTShares of Beneficial Interest Prospectus Supplement September 30, 2020

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectusprospectus supplement, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information documents incorporated by reference is an into this prospectus supplement contain important part of this prospectusinformation that you should read about us. The information following documents are incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in into this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 8M arch 13, 20172020, including the information incorporated by reference into our Annual Report on Form 10-K from our d efinitive proxy statement for the 2020 Annual Meeting o f Stockholders; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters period ended March 31, 20172020, filed with the SEC on May 9M ay 6, 2017, 2020; • our Quarterly Report on Form 10-Q for the period ended June 30, 20172020, filed with the SEC on August 9A ugust 5, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28M 2 020, 2017A ugust 21, March 302020, 2017and S eptember 18, May 262020; arch 10, 20172020, August 22M ay 4, 20172020, October 17, 2017, October 19, 2017, October 24, 2017 and November M ay 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● 2020, J uly 27, 2020, A ugust 4, 2020, A ugust 5, • the description of our common stock contained in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14S eptember 26, 20152016, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All ; and • all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus supplement and prior to the termination or completion of the offering of securities under this prospectus supplement shall be deemed to be incorporated by reference in this prospectus supplement and to be a part hereof from the date of filing such reports and other documents. We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of this prospectus supplement, or (ii) after the date of this prospectus supplement but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits which are specifically incorporated by reference into such documents. Requests should be directed to: Fulgent Genetics, Inc., Attn: Investor Relations, 0000 Xxxxx Xxxxx Xxxxxx, Temple City, California 91780, telephone: (000) 000-0000. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. PROSPECTUS $300,000,000 Common Stock Preferred Stock Debt Securities Warrants Rights Units From time to time, we may offer up to $300 million of any combination of the securities described in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these documents)offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. This prospectus may request not be used to consummate a copy sale of any securities unless accompanied by a prospectus supplement. Our common stock is traded on the Nasdaq Global Market under the symbol “FLGT.” On August 3, 2020, the last reported sales price of our common stock was $28.42 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. We will sell these materials securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any agents or underwriters are involved in the manner sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Additional InformationRisk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is August 12, 2020. TABLE OF CONTENTS Page A BOUT THIS PROSPECTUS 1 P ROSPECTUS SUMMARY 2 R ISK FACTORS 5 R ATIO OF EARNINGS TO FIXED CHARGES 6 S PECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 7 U SE OF PROCEEDS 10 P LAN OF DISTRIBUTION 11 D ESCRIPTION OF CAPITAL STOCK 13 D ESCRIPTION OF DEBT SECURITIES 18 D ESCRIPTION OF WARRANTS 24 D ESCRIPTION OF RIGHTS 26 D ESCRIPTION OF UNITS 28 L EGAL MATTERS 29 E XPERTS 29 W HERE YOU CAN FIND MORE INFORMATION 29 I NCORPORATION OF CERTAIN INFORMATION BY REFERENCE 29 D ISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 31 ABOUT THIS PROSPECTUS This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total dollar amount of $300,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading “Incorporation of Certain Information By Reference,” abovebefore investing in any of the securities offered. Up to $150,000,000 Common Stock THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. You should rely only on the information that we have provided or incorporated by reference in this prospectus, any applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you. We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus that we may authorize to be provided to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.”

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information documents listed below are incorporated by reference is an important part of into this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SECregistration statement: ● our Annual Report · Our annual report on Form 10-K for the fiscal year ended December 31April 30, 20162020 filed onJuly 7, filed with the SEC on March 82020, 2017as amended; ● our Quarterly Reports · Our quarterly report on Form 10-Q for the fiscal quarters quarter ended March July 31, 20172020, filed with onSeptember 14, 2020, and our quarterly report on Form 10-Q for the SEC on May 9quarter ended October 31, 2017, June 30, 20172020, filed with the SEC on August 9December 15, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports · Our current reports on Form 8-K filed with the SEC on February 28June 9, 2017, March 30, 2017, May 26, 20172020, August 2231, 20172020 and September 18, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● the · The description of our common stock contained in our Registration Statement registration statement on Form 8-AA filed with the SEC onJuly 31, filed on April 142017, 2015, including as updated by any amendments thereto or and reports filed for the purposes purpose of updating this such description. ; and · All reports and other documents that we file with the SEC under subsequently filed pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act after of 1934 (the date of this prospectus but before “Exchange Act”) prior to the termination of the offering offering, other than information furnished pursuant to Items 2.02 and 7.01 of the securities hereunder will also Form 8-K and any related exhibits, shall be considered deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” prospectus. Any statement contained in a document incorporated or deemed to the SEC will not be considered incorporated by reference into in this prospectusprospectus is modified or superseded for purposes of the prospectus to the extent that a statement contained in this prospectus or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectus, upon written or oral requestprospectus is delivered, a copy of any or all of the preceding documents information that are has been incorporated by reference (in this prospectus but not delivered with the prospectus. We are an Exchange Act reporting company and are required to file periodic reports on Form 10-K and 10-Q and current reports on Form 8-K. The SEC maintains an Internet website at xxx.xxx.xxx that contains reports, proxy and information statements, and other than exhibitsinformation regarding issuers, unless including the exhibits are specifically incorporated by reference into these documents)Company, that file electronically with the SEC. You may request also access our Exchange Act reports and proxy statements free of charge at xxx.xxxx.xxx/xxx-xxx-xxxxxxx. You may obtain a copy of these materials in the manner set forth under the heading “Additional Information,” above. any of our filings, at no cost, by contacting us at: 000 Xxxxx Xxxxxx, Xxxxx 000 Xxx Xxxx, Xxx Xxxx 00000 Attention: Corporate Secretary (000) 000-0000 18 Up to $150,000,000 3,000,000 Aspen Group, Inc. Common Stock PROSPECTUS SUPPLEMENTNorthland Capital Markets

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” into this prospectus supplement the information that we file with it into this prospectus, which the SEC. This means that we can disclose important information to you by referring you to those documents. The information Any statement contained in a document incorporated by reference is an important part in this prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus. The information prospectus supplement to the extent that a statement contained herein, or in any subsequently filed document, which also is incorporated by reference is considered herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to be constitute a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We hereby incorporate by reference into this prospectus supplement the following documents listed below (other than the portions of these documents deemed to be “furnished” or not deemed to be “filed,” including the portions of these documents that we have previously filed are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K, including any exhibits included with the SEC: ● such Items): • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with 2022 (the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017“Annual Report”); ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 282, 20172022 and March 18, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● • the description of our common capital stock contained in our Registration Statement Annual Report on Form 810-AK for the fiscal year ended December 31, 2019, filed with the SEC on April 14February 27, 20152020, pursuant to Section 12(b) of the Exchange Act, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than current reports on Form 8-K, or portions thereof, furnished under Items 2.02 or 7.01 of Form 8-K) (i) after the initial filing date of the registration statement of which this prospectus supplement forms a part and prior to the effectiveness of such registration statement and (ii) after the date of this prospectus but before supplement and prior to the termination of this offering shall be deemed to be incorporated by reference in this prospectus supplement from the offering date of filing of the securities hereunder documents, unless we specifically provide otherwise. Information that we file with the SEC will automatically update and may replace information previously filed with the SEC. To the extent that any information contained in any current report on Form 8-K or any exhibit thereto, was or is furnished to, rather than filed with the SEC, such information or exhibit is specifically not incorporated by reference. Upon written or oral request made to us at the address or telephone number below, we will, at no cost to the requester, provide to each person, including any beneficial owner, to whom this prospectus supplement is delivered, a copy of any or all of the information that has been incorporated by reference in this prospectus supplement (other than an exhibit to a filing, unless that exhibit is specifically incorporated by reference into that filing), but not delivered with this prospectus supplement. You may also be considered access this information on our website at xxx.xxxxxxxxxx.xxx by viewing the “SEC Filings” subsection of the “Investor Relations” menu. No additional information on our website is deemed to be part of or incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectussupplement. We undertake to provide without charge to each person have included our website address in this prospectus supplement solely as an inactive textual reference. Forte Biosciences, Inc. 0000 Xxxxxxx Xxxx Xxxxx, Xxxxxxxx 0 Dallas TX 75247 Attn: Investor Relations Tel: (including any beneficial owner000) who receives a copy of this prospectus000-0000 S-10 PROSPECTUS Forte Biosciences, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to Inc. $150,000,000 300,000,000 Common Stock PROSPECTUS SUPPLEMENTPreferred Stock Debt Securities

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectusprospectus supplement, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus supplement is an important part of this prospectus001-37590. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus supplement contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162022, as filed with the SEC on March 829, 20172023; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172023, as filed with the SEC on May 9onMay 4, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172023; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October onJanuary 17, 20172023, October 19February 3, 20172023, October 24April 21, 2017 2023 and November 27May 4, 2017 (other than any portions thereof deemed furnished 2023 in each case only to the extent the information in such report is filed and not filed)furnished; and ● • the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on April 14October 9, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All We also incorporate by reference into this prospectus supplement all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of the offering offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. Any statement in a document incorporated by reference or deemed to be incorporated by reference in this prospectus supplement shall be deemed to be modified or superseded for the purposes of this prospectus supplement to the extent that a statement contained herein or therein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein or therein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. We will furnish without charge to you, on written or oral request, a copy of any or all of the securities hereunder will also be considered documents incorporated by reference in this prospectus supplement, including exhibits to these documents. You should direct any requests for documents to Xxxxx Therapeutics, Inc., 000 Xxxxxxx Xxxx, Suite 400 Rockville, Maryland 20850; telephone: (000) 000-0000. Any statement contained in this prospectus supplement, the accompanying prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus from supplement or the date accompanying prospectus will be deemed to be modified or superseded for purposes of the filing document to the extent that a statement contained in this prospectus supplement or the accompanying prospectus or any other subsequently filed document that is deemed to be incorporated by reference herein or therein modifies or supersedes the statement. PROSPECTUS $375,000,000 of these reports Common Stock Preferred Stock Debt Securities, Warrants and/or Units From time to time, we may offer up to $375,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including pursuant to any applicable anti-dilution provisions. This prospectus provides you with a general description of the securities we may offer. Each time we offer securities, we will provide you with a prospectus supplement containing specific information about the terms of the securities being offered and documentsthe offering. We may also authorize one or more free writing prospectuses to be provided to you in connection with any offering. Any prospectus supplement may also add, update or change information contained in this prospectus. If information in any prospectus supplement or any related free writing prospectus is inconsistent with the information in this prospectus, then the information in that prospectus supplement or any related free writing prospectus will apply and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into in this prospectus. We undertake may offer and sell these securities to provide without charge or through one or more underwriters, dealers or agents, or directly to each person purchasers, on a continuous or delayed basis. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement with, between or among them will be set forth, or will be calculable from the information set forth, in an accompanying prospectus supplement or any related free writing prospectus. For more detailed information, see “Plan of Distribution” in this prospectus. Our common stock is traded on The Nasdaq Capital Market under the symbol “AVTX.” On April 11, 2023, the last reported sale price of our common stock was $3.10 per share. The aggregate market value of our outstanding common stock held by non-affiliates as of the date of this prospectus is $28.4 million based on 8,741,194 shares of outstanding common stock held by non-affiliates, and a per share price of $3.25 based on the closing sale price of our common stock on February 21, 2023 (a date within 60 days of the date hereof). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus is a part in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period if our public float, measured in accordance with such instruction, remains below $75.0 million. As of the date hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus. The applicable prospectus supplement or any beneficial owner) who receives related free writing prospectus will contain information, where applicable, as to any other listing on The Nasdaq Capital Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement or any related free writing prospectus. This prospectus may not be used by us to consummate a copy sale of securities unless accompanied by the applicable prospectus supplement. You should carefully read this prospectus, any prospectus supplement and any related free writing prospectus, together with additional information described in “Where You Can Find Additional Information” and “Incorporation of Certain Information by Reference”, before you invest in our securities. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5 of this prospectus, in any accompanying prospectus supplement, any related free writing prospectus and in the documents incorporated by reference herein and therein, to read about factors you should consider before investing in our securities. Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon written the accuracy or oral requestadequacy of this prospectus. Any representation to the contrary is a criminal offense. Prospectus dated May 2, 2023 ABOUT THIS PROSPECTUS This prospectus is part of a copy registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a shelf registration process. Under this shelf registration process, we may offer shares of our common stock, shares of our preferred stock, debt securities, warrants for such securities, or units consisting of a combination of any such securities, in one or more offerings, up to a total dollar amount of $375,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to any offering. This prospectus does not contain all of the preceding documents that are information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. Prospectus supplements and any related free writing prospectus may also add, update or change information contained or incorporated by reference (other than exhibitsin this prospectus. However, unless no prospectus supplement or any related free writing prospectus will fundamentally change the exhibits terms that are specifically set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements and any related free writing prospectus and the documents incorporated by reference into these documents)herein and therein, will include material information relating to the offering. You may request a copy of these materials in should carefully read this prospectus, the manner set forth applicable prospectus supplement and any related free writing prospectus, the information and documents incorporated herein and therein by reference and the additional information under the heading “Where You Can Find Additional Information,” abovebefore making an investment decision. Up You should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement or any related free writing prospectus. We have not authorized anyone to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTprovide you with information different from that contained or incorporated by reference in this prospectus or any prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus or any prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and that any information we have incorporated herein and therein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any prospectus supplement or any related free writing prospectus or any sale of a security. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find Additional Information.” To the extent there are inconsistencies between this prospectus, any prospectus supplement and any related free writing prospectus and any documents incorporated by reference, the document with the most recent date will control. This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus. The Information in this prospectus supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectus, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementprospectus. We incorporate by reference into this prospectus the information or documents listed below that we have previously filed with the SEC: ● • our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022; • the information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 8April 27, 20172022; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172022, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 20172022; ● • our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on January 26, 2022, February 282, 20172022, March 3015, 20172022, May 262, 20172022, August 22May 10, 20172022 and May 12, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● • the description of our common stock contained in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14May 1, 20152019, including any amendments thereto or reports filed as updated by Exhibit 4.3 to our Annual Report on Form 10-K for the purposes year ended December 31, 2020, and any amendment or report filed with the SEC for the purpose of updating this the description. All reports and other Any documents that we file with the SEC under Sections pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before and prior to the termination of the offering of the securities hereunder our common stock to which this prospectus relates will also automatically be considered deemed to be incorporated by reference into this prospectus and to be part hereof from the date of the filing of these reports and those documents, and will supersede the information herein; provided. We are not, however, incorporating by reference any documents or portions thereof that all reportsare not deemed “filed” with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statements in any such future filings will automatically be deemed to modify and other supersede any information in any document we previously filed with the SEC that we “furnish” is incorporated or deemed to be incorporated herein by reference to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written extent that statements in the later filed document modify or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)replace such earlier statements. You may can request a copy of these materials in filings, at no cost, by writing or telephoning us at the manner set forth under the heading “Additional Information,” above. following address or telephone number: Cortexyme, Inc. 000 Xxxx Xxxxx Xxxxxx Xxxxx Xxx Xxxxxxxxx, XX 00000 (000) 000-0000 Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTJefferies

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with it into this prospectus, which the SEC. This means that we can disclose important information to you by referring you to those documentsanother filed document. The Any information incorporated by reference referred to in this way is an important considered part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that prospectus from the date we file later that document. Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of the securities by means of this prospectus is terminated will automatically update and and, where applicable, supersede any information contained in this prospectus and any accompanying prospectus supplementor incorporated by reference in this prospectus. We Accordingly, we incorporate by reference the following documents listed below that we have previously or information filed with the SEC: ● our Our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020, which we filed with the SEC on May 14, 2020; ● Our Current Reports on Form 8-K filed with the SEC on January 22, 2020, March 5, 2020, April 21, 2020, April 23, 2020, May 11, 2020 and May 29, 2020; ● Our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, which we filed with the SEC on March 830, 20172020; ● our Quarterly Reports Our Amended Annual Report on Form 10-Q K/A for the fiscal quarters year ended March December 31, 20172019, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A which we filed with the SEC on April 1029, 20172020; ● our Current Reports on Form 8-K All documents filed by us in accordance with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after April 14, 2017 and prior to effectiveness of the registration statement containing this prospectus, other than documents or information deemed furnished and not filed in accordance with SEC rules; ● The description of our capital stock contained in our Current Report on Form 8-K filed with the SEC on April 13, 2017; and ● All documents filed by us in accordance with Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus but and before the termination of the an offering under this prospectus, other than documents or information deemed furnished and not filed in accordance with SEC rules. We will provide a copy of the securities hereunder will also be considered documents we incorporate by reference, at no cost, to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into any person who received this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may To request a copy of any or all of these materials in the manner set forth under the heading “Additional Information,” abovedocuments, you should write or telephone us at: Investor Relations, Pacific Ethanol, Inc., 000 Xxxxxxx Xxxx, Xxxxx 0000, Xxxxxxxxxx, Xxxxxxxxxx 00000, (000) 000-0000. Up to In addition, each document incorporated by reference is readily accessible on our website at xxx.xxxxxxxxxxxxxx.xxx. $150,000,000 30,000,000 PACIFIC ETHANOL, INC. Common Stock PROSPECTUS SUPPLEMENTX. X. Xxxxxxxxxx & Co.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The documents instead of having to repeat the information incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● SEC (Commission File No. 001-36483) and any future filings (including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we will make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act until the termination of the offering of the securities covered by this prospectus (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K): • our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 (including the information specifically incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● 2019 from our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement definitive proxy statement on Schedule 14A filed with the SEC on April 10, 2017(other than information furnished rather than filed)); ● • our Current Reports on Form 8-K and any amendments thereto (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed with the SEC on February 28, 2017, March the following dates: January 30, 20172020, May 26February 6, 20172020, August 22February 7, 2017, October 17, 2017, October 2020 and February 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● • the description of our common stock contained in our Registration Statement registration statement on Form 8-AA filed with the SEC on June 6, filed on April 14, 20152014, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of Any statement contained in this prospectus but before the termination of the offering of the securities hereunder will also be considered or in a document incorporated or deemed to be incorporated by reference into this prospectus from the date will be deemed to be modified or superseded for purposes of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” this prospectus to the SEC will not extent that a statement contained in this or any other subsequently filed document that is deemed to be considered incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should rely only on information contained in, or incorporated by reference into, this prospectus. We undertake have not authorized anyone to provide without charge to each person (including any beneficial owner) who receives a copy of you with information different from that contained in this prospectus, upon written prospectus or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)in this prospectus. You may can request a copy of these materials filings, at no cost, by writing or telephoning us at the following address or telephone number: Miragen Therapeutics, Inc. 0000 Xxxxxxx Xxxx Boulder, CO 80301 Attn: Investor Relations Tel: (000) 000-0000 Email: xxxxxxxxxxxxxxxxx@xxxxxxxxx.xxx This prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more information about us and the shares in this offering. Because information about documents referred to in this prospectus is not always complete, you should read the manner set forth under full documents which are filed as exhibits to the heading “Additional Information,” aboveregistration statement. Up to You may read and copy the full registration statement and its exhibits at the SEC’s public reference rooms or its website. $150,000,000 50,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Xxxxxxxxx

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference information that we file with it into this prospectus, which document. This means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectusprospectus supplement, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934 made subsequent to the date of this prospectus supplement until the termination of the offering of the securities described in this prospectus supplement (other than information in such filings that was “furnished,” under applicable SEC rules, rather than “filed”). These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. We incorporate by reference the following documents or information that we have previously filed with the SEC: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021 filed with the SEC on March 14, 2022 (the “2021 Form 10-K”) (including the portions of our Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 8April 21, 20172022, incorporated by reference therein); ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports Report on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May January 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022 ; and ● • the description of our common stock ordinary shares and ADSs contained in our Registration Statement registration statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after on April 30, 2015, as updated by Exhibit 4.4 to the date 2021 Form 10-K, including the “Description of Ordinary Shares” and the “Description of American Depositary Shares” contained therein and any amendment or report filed for the purpose of updating such description. Any statement contained in this prospectus but before the termination of the offering of the securities hereunder will also be considered or contained in a document incorporated or deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” be deemed to be modified or superseded to the SEC will not extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written modifies or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)supersedes such statement. You may request a copy of these materials in filings at no cost, by writing or telephoning us at the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTfollowing address: Adaptimmune Therapeutics plc Attn: Company Secretary 00 Xxxxxxx Xxxxxx, Xxxxxx Xxxx Abingdon, Oxfordshire OX14 4RX United Kingdom

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-36812. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162018, filed with the SEC on March 86, 20172019; ● • our Quarterly Reports Annual Report on Form 10-Q K/A for the fiscal quarters year ended March December 31, 20172018, filed with the SEC on May 9April 16, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172019; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on January 4, 2019 and February 2815, 20172019, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished to the extent the information in such reports is filed and not filed)furnished; and ● • the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on April 14January 23, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits that are specifically incorporated by reference into these such documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” abovefilings by writing us at 00 Xx. Xxxxx Xxxxxx, 6th Floor, Boston, MA 02116 or telephoning us at (000) 000-0000. Up to $150,000,000 25,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Ladenburg Xxxxxxxx July 2, 2021

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which prospectus and any accompanying prospectus supplement the information we have filed with the SEC. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectusanother document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will also be deemed to be incorporated by reference into this prospectus and to be a part hereof from the date of filing of such documents and will automatically update and supersede previously filed information, including information contained in this document. We incorporate by reference into this prospectus and any accompanying prospectus supplement. We incorporate by reference supplement the following documents listed below that we have previously filed with the SEC: ● our • Our Annual Report on Form 10F orm 20-K F for the fiscal year ended December 31, 20162018, filed with the SEC on March 85, 20172019; ● our Quarterly • Our Reports on Form 106-Q for the fiscal quarters ended March 31, 2017, filed with K furnished to the SEC on May M 2 019 and J uly 18, 2019; arch 5, 2019, M arch 29, 2019, M ay 9, 20172019, June 30M ay 20, 20172019, filed with the SEC on August 9J une 19, 2017 and September 302019, 2017, filed with the SEC on November J uly 8, 2017; ● our Proxy Statement • the information contained in Exhibits 9 9.1 (Unaudited Condensed Consolidated Financial Statements) and 9 9.2 (Management’s Discussion and Analysis of Financial Condition and Results of Operations) to the Report on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8F orm 6-K filed with the SEC on February 28August 7, 20172019; • the information contained in E xhibit 99.1 (Risk Factors) to the Report on F orm 6-K filed with the SEC on August 7, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2019; and ● the • The description of our common stock shares contained in our Registration Statement on Form F orm 8-A, filed with the SEC on April 14January 23, 20152017, including any amendments thereto or reports filed for the purposes of updating this description. All We are also incorporating by reference all subsequent annual reports and other documents on Form 20-F that we file with the SEC under Sections 13(a), 13(c), 14 and those of our current reports on Form 6-K that we furnish to the SEC that we specifically identify in such form or 15(d) of the Exchange Act after the date of this in any applicable prospectus but before the termination of the offering of the securities hereunder will also be considered to be supplement as being incorporated by reference into this prospectus from or such prospectus supplement after the date of the filing of these reports hereof and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” prior to the SEC will not be considered incorporated by reference into completion of an offering of securities under this prospectus. We undertake to provide will furnish without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, upon on written or oral request, a copy of any or all of the preceding documents that are incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents, either in writing to ObsEva SA, Attn: Chief Financial Officer, Chemin des Aulx, 12, 1228 Plan-les-Ouates, Geneva, Switzerland or by telephone at +00 00 000 00 00. You also may access these filings on our website at xxx.xxxxxx.xxx. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than exhibits, unless those filings with the exhibits are SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus). Any statement contained in a document incorporated or deemed to be incorporated by reference into these documents)in this prospectus or any prospectus supplement will be deemed modified, superseded or replaced for purposes of this prospectus or any prospectus supplement to the extent that a statement contained in any other subsequently filed document that also is or is deemed to be incorporated by reference in this prospectus or any prospectus supplement modifies, supersedes or replaces such statement. You may request Any statement that is modified or superseded will not constitute a copy part of these materials in the manner set forth under the heading “Additional Information,” abovethis prospectus or prospectus supplement, except as modified or superseded. 37 Up to $150,000,000 50,000,000 Common Stock Shares PROSPECTUS SUPPLEMENTSUPPLEMENT SVB Leerink

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “We incorporate by reference” reference into this prospectus supplement and the accompanying prospectus the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documentsthe documents that contain such information. The information incorporated by reference is an important part of this prospectusprospectus supplement. The information incorporated by reference is considered to be a part of this prospectus, and information Information that we file later subsequently with the SEC will automatically update and supersede this prospectus supplement. In other words, in the case of a conflict or inconsistency between information set forth in this prospectus supplement and/or information incorporated by reference into this prospectus supplement, you should rely on the information contained in this prospectus and any accompanying prospectus supplementthe document that was filed later. We incorporate by reference the documents listed below that and any filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, (i) after the initial filing of this prospectus supplement, and (ii) on or after the date of this prospectus supplement and prior to the termination of the offering made pursuant to this prospectus supplement and the accompanying prospectus: ● our • Our Annual Report on Form 10-K for the fiscal year ended December 31February 3, 20162024, filed with the SEC on March 826, 2017; ● our Quarterly Reports 2024, as amended by the Annual Report on Form 10-Q for K/A filed with the fiscal quarters ended SEC on March 3127, 20172024; • The information specifically incorporated by reference into our Annual Report from our definitive proxy statement on Schedule 14A, filed with the SEC on May 9, 2017, June April 30, 20172024; • Our Current Reports on Form 8-K, filed with the SEC on August 9March 26, 2017 and September 302024, 2017April 4, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 20172024, May 26, 2017, August 22, 2017, October 17, 20172024, October 19May 17, 20172024, October May 24, 2017 2024 and November 27June 7, 2017 (other than any portions thereof deemed furnished and not filed)2024; and ● the • The description of our Class A common stock contained in our Registration Statement on Form 8-AA filed October 3, filed on April 14, 20152005, including any amendments thereto amendment or reports report filed for the purposes of updating this description. All reports and other documents that we file with the SEC for the purpose of updating such description. Nothing in this prospectus shall be deemed to incorporate information furnished to but not filed with the SEC pursuant to Item 2.02 or Item 7.01 of Form 8-K (or corresponding information furnished under Sections 13(aItem 9.01 or included as an exhibit to Form 8-K). We encourage you to read our periodic and current reports. We think these reports provide additional information about our Company which prudent investors find important. We will provide to each person, 13(c)including any beneficial owner, 14 to whom a prospectus is delivered, at no cost, a copy of any or 15(d) all of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be documents that are incorporated by reference into this prospectus from supplement but not delivered with this prospectus supplement, upon written or telephonic request to us at our principal executive offices at the following telephone number and address: 000 Xxxxxxxx Xxxxxxx, Xxxxxxxxx, Xxxxx 00000, (000) 000-0000, Attn: Investor Relations. You should rely only on the information incorporated by reference or provided in this prospectus supplement, the accompanying prospectus, or any other offering materials we may use. We have not authorized any person to provide information other than that provided in this prospectus supplement, the accompanying prospectus, or any other offering materials we may use. You should assume that the information in this prospectus supplement, the accompanying prospectus, and any other offering materials we may use is accurate only as of the date on its cover page and that any information in a document we have incorporated by reference is accurate only as of the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information document incorporated by reference. The statements that we “furnish” to make in this prospectus supplement, the SEC will not be considered accompanying prospectus, or in any document incorporated by reference into in this prospectus. We undertake prospectus supplement or the accompanying prospectus about the contents of any other documents are not necessarily complete, and are qualified in their entirety by referring you to provide without charge to each person (including any beneficial owner) who receives a copy copies of this prospectus, upon written or oral request, a copy of all of the preceding those documents that are filed as exhibits to the registration statement, of which this prospectus supplement forms a part, or as an exhibit to the documents incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)reference. You may request a copy can obtain copies of these materials in documents from the manner set forth under the heading “Additional Information,” SEC or from us, as described above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTGAMESTOP CORP.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-35890. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● our • Our Annual Report on Form F orm 10-K and 1 0-K/A for the fiscal year ended December 31, 2016, filed with the SEC 2020; • Our Quarterly Report on March 8, 2017; ● our Quarterly Reports on Form F orm 10-Q for the fiscal quarters quarter ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172021; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Our Current Reports on Form 8-K and Form 8-K/A filed with the SEC on February J anuary 5, 2021, J anuary 28, 20172021, March 30M arch 29, 20172021, May 26J une 11, 20172 021, August 22J une 23, 20172021, October 17J une 28, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2021 (other than any portions thereof deemed the information furnished pursuant to Item 7.01 and not filedExhibit 99.1), J uly 1, 2021, J uly 7, 2 021, J uly 12, 2021 and J uly 16, 2021; and ● the • The description of our common stock contained set forth in our Registration Statement the registration statement on Form F orm 8-AA registering our common stock under Section 12 of the Exchange Act, which was filed with the SEC on April 1425, 20152013, including any amendments thereto or reports filed for the purposes of updating this such description. All We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits that are specifically incorporated by reference into these such documents). You may request should direct any requests for documents to Tempest Therapeutics, Inc., Attn: Investor Relations, 0000 Xxxxxxxxx Xxxxx; Xxxxx 000 Xxxxx Xxx Xxxxxxxxx, XX 00000. Any statement contained in this prospectus or contained in a copy of these materials document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded to the extent that a statement contained in the manner set forth under the heading “Additional Information,” abovethis prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus, modifies or supersedes such statement. Up to $150,000,000 100,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Xxxxxxxxx

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-37590. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162020, as filed with the SEC on March 8, 20172021; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28onJanuary 5, 20172021, January 7, 2021, January 8, 2021 and March 301, 20172021, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished in each case only to the extent the information in such report is filed and not filed)furnished; and ● • the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on April 14October 9, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8- K, as well as proxy statements. We undertake to provide will furnish without charge to each person (including any beneficial owner) who receives a copy of this prospectusyou, upon on written or oral request, a copy of any or all of the preceding documents that are incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents to Cerecor Inc., 000 Xxxxxxx Xxxx, Suite 400 Rockville, Maryland 20850; telephone: (other than exhibits, unless the exhibits are specifically 000) 000-0000. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into these documents)this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to UP TO $150,000,000 Common Stock 50,000,000 COMMON STOCK PROSPECTUS SUPPLEMENTSUPPLEMENT Cantor RBC Capital Markets

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus. The Information in this prospectus supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectus, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementprospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have previously filed with the SEC: ● SEC (Commission File No. 001-38906): • our Annual Report on Form 10-K for the fiscal year ended December March 31, 20162020, filed with the SEC on March 8June 29, 20172020; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 20172020, filed with the SEC on August 912, 2017 and 2020; • our Quarterly Report on Form 10-Q for the quarter ended September 30, 20172020, filed with the SEC on November 812, 20172020; ● • the information specifically incorporated by reference in our Proxy Statement Annual Report on Schedule 14A Form 10-K for the year ended March 31, 2020, fromour definitive proxy statement relating to our 2020 annual meeting of stockholders, filed with the SEC on April 10July 9, 20172020; ● • our Current Reports on Form 8-K filed with the SEC on February 28onMay 14, 2017, March 30, 2017, May 26, 20172020, August 2221, 20172020, October 17August 25, 20172020 (solely with respect to Item 8.01) and September 18, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● • the description of our common stock contained in our Registration Statement on Form registration statement onForm 8-AA filed with the SEC on May 9, filed on April 14, 20152019, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act Act, including those made after the date of the initial filing of the registration statement of which this prospectus but before is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities hereunder shares of our common stock made by this prospectus and will also be considered to be incorporated by reference into become a part of this prospectus from the date of that such documents are filed with the filing of these reports SEC. Information in such future filings updates and documents, and will supersede supplements the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into provided in this prospectus. We undertake Any statements in any such future filings will automatically be deemed to provide without charge modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are be incorporated herein by reference (other than exhibits, unless to the exhibits are specifically incorporated by reference into these documents)extent that statements in the later filed document modify or replace such earlier statements. You may can request a copy of these materials in filings, at no cost, by writing or telephoning us at the manner set forth under the heading “Additional Information,” above. following address or telephone number: Immunovant, Inc. 000 Xxxx 00xx Xxxxxx Xxx Xxxx, XX 00000 (917) 580-3099 Attn: Secretary Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTSVB Leerink

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-37590. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162022, as filed with the SEC on March 829, 20172023; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October onJanuary 17, 20172023 and February 3, October 192023, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished in each case only to the extent the information in such report is filed and not filed)furnished; and ● • the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on April 14October 9, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered offering. These documents include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. 18 Any statement in a document incorporated by reference or deemed to be incorporated by reference into in this prospectus from shall be deemed to be modified or superseded for the date purposes of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” this prospectus to the SEC will not extent that a statement contained herein or therein or in any other subsequently filed document which also is incorporated or deemed to be considered incorporated by reference into herein or therein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. We undertake to provide will furnish without charge to each person (including any beneficial owner) who receives a copy of this prospectusyou, upon on written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsin this prospectus, unless the including exhibits are specifically incorporated by reference into to these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” aboveshould direct any requests for documents to Xxxxx Therapeutics, Inc., 000 Xxxxxxx Xxxx, Suite 400 Rockville, Maryland 20850; telephone: (000) 000-0000. Up to $150,000,000 9,032,567 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Xxxxxxxxxxx & Co.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” into this prospectus information contained in documents that we file with it into this prospectus, which it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference into this prospectus is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that and any future filings we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after prior to the date of this prospectus but before the termination of that the offering of the securities hereunder will by means of this prospectus is completed or terminated, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules, including Current Reports on Form 8-K furnished under Item 2.02 or Item 7.01, including any financial statements or exhibits relating thereto furnished pursuant to Item 9.01): ● our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021; ● our Current Reports on Form 8-K, filed with the SEC on February 25, 2021 (excluding such items as deemed furnished in such Form 8-K), March 24, 2021 and March 29, 2021, and our Current Reports on Form 8-K/A, filed with the SEC on March 20, 2020 and August 11, 2020; ● our Definitive Proxy Statement on Schedule 14A, filed with the SEC on March 29, 2021; ● the description of our common stock contained in our Registration Statement on Form 8-A filed with the SEC on July 2, 2014, including all amendments and reports filed for purposes of updating such description; and ● the description of our Series A Preferred Stock contained in our Registration Statement on Form 8-A/A filed with the SEC on October 19, 2015, including all amendments or reports filed for the purpose of updating such description. Any statement incorporated by reference in this prospectus from an earlier dated document that is inconsistent with a statement contained in this prospectus or in any other document filed after the date of the earlier dated document, but prior to the date hereof, which also be considered to be is incorporated by reference into this prospectus, shall be deemed to be modified or superseded for purposes of this prospectus from by such statement contained in this prospectus or in any other document filed after the date of the filing of these reports and documentsearlier dated document, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” but prior to the SEC will not be considered date hereof, which also is incorporated by reference into this prospectus. We undertake to provide without charge to each person (Any person, including any beneficial owner) who receives a copy , to whom this prospectus is delivered may request copies of this prospectus, upon written or oral request, a copy of all prospectus and any of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into this prospectus, without charge, by written or oral request directed to XxxxXxxxx, 0 Xxxxx Xxxx, Somerset, New Jersey, 08873, telephone: (000) 000-0000, x 133. ABOUT CARECLOUD, INC. CareCloud, Inc., formerly MTBC, Inc. (“CareCloud” and together with its consolidated subsidiaries, the “Company”, “we”, “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, together with related business services, to healthcare providers and hospitals throughout the United States. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. At a high level, these documentssolutions can be categorized as follows: ● RCM services, which include end-to-end medical billing, eligibility, analytics, and related services, all of which can often be provided either with our technology platform or through a third-party system; ● Proprietary healthcare IT software solutions, which can be bundled with our RCM services, including: ○ EHRs, which are easy to use, integrated with our business services or offered as Software-as-a-Service (“SaaS”) solutions, and allow our healthcare provider clients to deliver better patient care, document their clinical visits effectively and thus potentially qualify for government incentives, reduce documentation errors and reduce paperwork; ○ PM software and related tools, which support our clients’ day-to-day business operations and workflows; ○ Mobile Health (“mHealth”) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services; ○ Telehealth solutions, which allow healthcare providers to conduct remote patient visits; ○ Healthcare claims clearinghouse, which enables our clients to electronically scrub and submit claims to, and process payments from, insurance companies; and ○ Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients. ● Medical Office Practice Management Services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services and administrative support staff. We also provide management, bill-paying and financial advisory services. Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs. The modernization of the healthcare industry is transforming nearly every aspect of a healthcare organization from policy to providers; clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer. We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands. We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 600 experienced health industry experts throughout the United States. These experts who are supported by our highly educated and specialized offshore workforce of approximately 3,100 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model also allows us to be a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud. Adoption of our RCM solutions requires little or no upfront expenditure by a client. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients, as the vast majority of our revenues are based on a percentage of our clients’ collections. The fees we charge for our complete, integrated, end-to-end solution are very competitive. We estimate that we currently provide one or more services to more than 40,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals, representing 80 specialties and subspecialties in 50 states. In addition, we served approximately 200 clients which are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services, and are based in part upon estimates where the precise number of practices or providers is unknown. We service clients ranging from small practices to large groups and health systems. Our clients span from the single doctor independent medical practice to a large, 2,200 provider of physical, occupational and speech therapy services organization located across multiple states, and a large major academic medical institution with a service area covering millions of patients. On July 23, 2014, the Company, under the name Medical Transcription Billing, Corp. completed its initial public offering (“IPO”) of common stock. The Company sold approximately four million shares at a price to the public of $5.00 per share. In November 2015, the Company completed a public offering of its 11% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Preferred Stock”). You may request The Company sold 231,616 shares at a copy price of these materials $25.00 per share and received net proceeds of approximately $4.7 million. In July 2016, the Company sold an additional 63,040 shares of Preferred Stock and received net proceeds of approximately $1.3 million. In 2017, the Company raised a total of $16.4 million in net proceeds from a series of additional offerings totaling approximately 765,000 shares of Preferred Stock, all at $25.00 per share. In May 2017, the Company completed a registered direct offering of one million shares of its common stock at $2.30 per share, raising net proceeds of approximately $2.0 million. During 2018, 2019 and 2020, the Company issued 1,020,000, 373,000 and 1,932,000 shares of Preferred Stock, respectively and received net proceeds of approximately $22.8 million, $9.6 million and $44.5 million, respectively. During 2016, the Company purchased substantially all of the assets of MediGain, LLC, including its subsidiary Millennium Practice Management Associates, LLC and two offshore subsidiaries in India and Sri Lanka through the Company’s wholly owned subsidiary, MTBC Acquisition, Corp. In 2017, the Company purchased substantially all of the assets of Washington Medical Billing, LLC. In 2018, the Company purchased substantially all of the assets of Orion Healthcorp, Inc., through the Company’s wholly owned subsidiaries at that time MTBC Health, Inc. and MTBC Practice Management, Corp. In 2019, the Company purchased substantially all of the assets of Etransmedia Technology, Inc. through the Company’s wholly owned subsidiary at that time MTBC-Med, Inc. On June 21, 2019, the Company’s shareholders approved an increase in the manner set forth under Company’s authorized shares, from nineteen million shares (19,000,000) of common stock and four million (4,000,000) shares of preferred stock, to twenty-nine million (29,000,000) shares of common stock and seven million (7,000,000) shares of preferred stock, respectively, and the heading Company amended its Articles of Incorporation to reflect this change. On January 8, 2020, through a merger with a subsidiary, the Company acquired CareCloud Corporation (“Additional Information,” aboveCCC”), whose name we subsequently took, which has developed a highly acclaimed cloud-based platform including EHR, PM and patient experience capabilities. Up The Company paid $11.9 million in cash, assumed a working capital deficiency of approximately $5.1 million and issued 760,000 shares of the Company’s Series A Preferred Stock and two million warrants for the purchase of the Company’s common stock at prices ranging from $7.50 to $150,000,000 Common 10.00 per share. On June 16, 2020, the Company purchased all of the issued and outstanding capital stock of Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively “Meridian” and sometimes referred to as “Meridian Medical Management”). Meridian is in the business of providing medical billing, revenue cycle management, electronic medical records, medical coding and related services. The total consideration paid at closing was $11.9 million in cash, 200,000 shares of the Company’s Series A Preferred Stock PROSPECTUS SUPPLEMENTplus warrants to purchase 2,250,000 shares of the Company’s common stock, with an exercise price of $7.50 per share and a term of two years. The Company also assumed Xxxxxxxx’s negative net working capital and certain long-term lease liabilities with an aggregate value of approximately $4.8 million. In February 2021, the Company’s Board of Directors approved an amendment to our Articles of Incorporation to change our name to CareCloud, Inc. Including the employees of our subsidiaries, as of April 9, 2021, the Company employed approximately 3,800 people worldwide on a full-time basis. We also utilize the services of a small number of part-time employees. The RCM service industry is highly fragmented, with many local and regional RCM companies serving small medical practices and hospitals. We believe that the industry is ripe for consolidation and that we can achieve significant growth through acquisitions. We further believe that it is becoming increasingly difficult for traditional RCM companies to meet the growing technology and business service needs of healthcare providers without a significant investment in an information technology infrastructure. Since the Company’s IPO, we have acquired substantially all of the assets of 16 RCM companies. Although the specific arrangements have varied with each transaction, typical arrangements include a discounted price, consideration which is sometimes tied to revenues from the customer relationships acquired, and structuring the acquisition as an asset purchase so as to limit our liability. We typically leverage our technology and our cost-effective offshore team to reduce costs promptly after the transaction closes, although there will be initial costs associated with the integration of the acquired business with our existing operations. In addition to growing through acquisitions, we also drive organic growth through various strategies, including customer referrals, channel partnerships, online marketing and tradeshows. Our acquisitive growth also supports our organic growth initiatives by enhancing our capabilities, physical presence, and universe of referrals and referenceable clients. Our principal executive offices are located at 0 Xxxxx Xxxx, Somerset, New Jersey, 08873, and our main telephone number is (000) 000-0000.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “We incorporate by reference” reference into this prospectus supplement and the accompanying prospectus the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documentsthe documents that contain such information. The information incorporated by reference is an important part of this prospectusprospectus supplement. The information incorporated by reference is considered to be a part of this prospectus, and information Information that we file later subsequently with the SEC will automatically update and supersede this prospectus supplement. In other words, in the case of a conflict or inconsistency between information set forth in this prospectus supplement and/or information incorporated by reference into this prospectus supplement, you should rely on the information contained in this prospectus and any accompanying prospectus supplementthe document that was filed later. We incorporate by reference the documents listed below that and any filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, (i) after the initial filing of this prospectus supplement, and (ii) on or after the date of this prospectus supplement and prior to the termination of the offering made pursuant to this prospectus supplement and the accompanying prospectus: ● our • Our Annual Report on Form 10-K for the fiscal year ended December 31February 3, 20162024, filed with the SEC on March 826, 2017; ● our Quarterly Reports 2024, as amended by the Annual Report on Form 10-Q for K/A filed with the fiscal quarters ended SEC on March 3127, 20172024; • The information specifically incorporated by reference into our Annual Report from our definitive proxy statement on Schedule 14A, filed with the SEC on May 9, 2017, June April 30, 20172024; • Our Current Reports on Form 8-K, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 20172024, August 22April 4, 2017, October 2024 and May 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2024; and ● the • The description of our Class A common stock contained in our Registration Statement on Form 8-AA filed October 3, filed on April 14, 20152005, including any amendments thereto amendment or reports report filed for the purposes of updating this description. All reports and other documents that we file with the SEC for the purpose of updating such description. Nothing in this prospectus shall be deemed to incorporate information furnished to but not filed with the SEC pursuant to Item 2.02 or Item 7.01 of Form 8-K (or corresponding information furnished under Sections 13(aItem 9.01 or included as an exhibit to Form 8-K). We encourage you to read our periodic and current reports. We think these reports provide additional information about our Company which prudent investors find important. We will provide to each person, 13(c)including any beneficial owner, 14 to whom a prospectus is delivered, at no cost, a copy of any or 15(d) all of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be documents that are incorporated by reference into this prospectus from supplement but not delivered with this prospectus supplement, upon written or telephonic request to us at our principal executive offices at the following telephone number and address: 000 Xxxxxxxx Xxxxxxx, Xxxxxxxxx, Xxxxx 00000, (000) 000-0000, Attn: Investor Relations. You should rely only on the information incorporated by reference or provided in this prospectus supplement, the accompanying prospectus, or any other offering materials we may use. We have not authorized any person to provide information other than that provided in this prospectus supplement, the accompanying prospectus, or any other offering materials we may use. You should assume that the information in this prospectus supplement, the accompanying prospectus, and any other offering materials we may use is accurate only as of the date on its cover page and that any information in a document we have incorporated by reference is accurate only as of the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information document incorporated by reference. The statements that we “furnish” to make in this prospectus supplement, the SEC will not be considered accompanying prospectus, or in any document incorporated by reference into in this prospectus. We undertake prospectus supplement or the accompanying prospectus about the contents of any other documents are not necessarily complete, and are qualified in their entirety by referring you to provide without charge to each person (including any beneficial owner) who receives a copy copies of this prospectus, upon written or oral request, a copy of all of the preceding those documents that are filed as exhibits to the registration statement, of which this prospectus supplement forms a part, or as an exhibit to the documents incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)reference. You may request a copy can obtain copies of these materials in documents from the manner set forth under the heading “Additional Information,” SEC or from us, as described above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTGAMESTOP CORP.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The documents instead of having to repeat the information incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC on March 81, 20172022; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172022, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172022; ● • our Definitive Proxy Statement on Schedule 14A filed with the SEC on April May 2, 2022 (solely to the extent specifically incorporated by reference into the Annual Report on Form 10-K for the year ended December 31, 20172021); ● • our Current Reports on Form 8-K filed with the SEC on February 28March 21, 20172022 and April 18, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2022 (other except for information contained therein which is furnished rather than any portions thereof deemed furnished and not filed); and ● • the description of our common stock contained in our Registration Statement on Form 8-A, filed pursuant to Section 12(b) of the Exchange Act, on April 14October 1, 20151999, as updated by Exhibit 4.6 to our Annual Report on Form 10-K for the year ended December 31, 2020, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All reports ; and other • all documents that we file filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus but before and prior to the termination of the offering of the underlying securities hereunder will also be considered to be incorporated by reference into this prospectus from the date (excluding any portions of the filing of these reports and documents, and will supersede the information herein; provided, however, such documents that all reports, exhibits and other information that we are deemed “furnishfurnished” to the SEC will not be considered incorporated by reference into this prospectuspursuant to applicable rules and regulations). We undertake to provide will furnish without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, upon on written or oral requestrequest of such person, a copy of any or all of the preceding documents that are incorporated by reference in this prospectus (other than exhibitsnot including exhibits to such documents, unless the such exhibits are specifically incorporated by reference in this prospectus or into these such documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to should direct any requests for documents to: Plug Power Inc. 000 Xxxxxx Xxxxxx Xxxx Xxxxxx, Xxx Xxxx, 00000 Attention: General Counsel Telephone: (000) 000-0000 $150,000,000 1,000,000,000 Common Stock PROSPECTUS SUPPLEMENT

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by referenceincorporate” into this prospectus information that we file with it into this prospectus, which the SEC in other documents. This means that we can disclose important information to you by referring you to those documentsother documents that contain that information. The Any information incorporated that we incorporate by reference into this prospectus is an important considered part of this prospectus. The information incorporated by reference is considered to be a part of Information contained in this prospectus, and information that we file later with the SEC will automatically update in the future and supersede information contained incorporate by reference in this prospectus automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any accompanying prospectus supplementstatement so superseded will be deemed not to constitute a part of this prospectus. We incorporate by reference reference, as of their respective dates of filing, the documents listed below that we have previously filed with the SECSEC and any documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, between the date of this prospectus supplement and the date on which the offering of the securities covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been “furnished” and not “filed” in accordance with SEC rules: ● · our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, as filed with the SEC on March 8February 20, 20172020; ● · our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 20172020, June 30, 2020, and September 30, 2020, as filed with the SEC on May 97, 20172020, June 30August 13, 20172020, filed with the SEC on August 9and November 12, 2017 and September 302020, 2017, filed with the SEC on November 8, 2017respectively; ● · our Definitive Proxy Statement on Schedule 14A 14A, as filed with the SEC on April 29, 2020 (to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended December 31, 20172019); ● · our Current Reports on Form 8-K as filed with the SEC on February 28, 2017, March 30, 2017, each of May 26, 2017, August 22, 20172020, October 17and June 22, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● · the description of our common stock contained in Exhibit 4.1 to our Registration Statement Annual Report on Form 810-A, filed on April 14, 2015, including any amendments thereto or reports filed K for the purposes of updating this description. All reports and other documents that we file year ended December 31, 2019, as filed with the SEC under Sections 13(a)on February 20, 13(c), 14 2020. These filings have not been included in or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into delivered with this prospectus. We hereby undertake to provide without charge to each person (person, including any beneficial owner) who receives a copy of , to whom this prospectusprospectus is delivered, upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (into this prospectus, but not delivered with the prospectus, other than exhibits, exhibits to such documents unless the such exhibits are specifically incorporated by reference into these documents)the documents that this prospectus incorporates. To request such materials, please contact Xx. Xxxxxx Xxxxxxxxx, our Corporate Secretary, at c/o Corporate Secretary, VolitionRx Limited, 00000 Xxx Xxxx Xxxxxxx, Xxxxx 000, Xxxxxxxx Xxxx X, Xxxxxx, Xxxxx 00000, or by email at xxxxxx@xxxxxxxx.xxx. These documents are also available free of charge through the Investors section on our website at xxxx://xxx.xxxxxxxx.xxx as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. You should rely only on the information contained in this prospectus, in any document incorporated by reference herein, or in any free writing prospectuses we may request provide to you in connection with this offering. Neither we nor the Designated Agents have authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, and in the documents incorporated by reference herein, is accurate only as of the date such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates. WHERE YOU CAN FIND MORE INFORMATION We file annual, quarterly and current reports and other information with the SEC. Our filings with the SEC are available from the SEC’s internet site at xxxx://xxx.xxx.xxx, which contains reports, proxy and information statements, and other information regarding issuers that file electronically. This prospectus supplement and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is included in the registration statement. The registration statement contains more information regarding us and our securities, including certain exhibits. You can obtain a copy of the registration statement from the SEC’s website. $100,000,000 VOLITIONRX LIMITED Common Stock Warrants Units We may offer and sell, from time to time in one or more offerings, any combination of common stock, warrants exercisable for shares of our common stock, or units having an aggregate initial offering price not to exceed $100,000,000. The units may consist of any combination of securities described in this prospectus. This prospectus provides a general description of the securities we may offer. We will provide you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplement may also add, update or change information in this prospectus. You should read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference herein or therein, carefully before you invest in any of the securities offered pursuant to this prospectus. This prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities. These securities may be sold directly by us, through dealers or agents designated from time to time, to or through underwriters or dealers or through a combination of these materials methods on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. We will describe the plan of distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the manner sale of any securities with respect to which this prospectus is being delivered, we will set forth in a prospectus supplement the names of such agents, underwriters or dealers and any applicable fees, commissions, discounts and over-allotment options. We will also set forth in a prospectus supplement the price to the public of such securities and the net proceeds that we expect to receive from such sale. Our common stock is currently quoted on the NYSE American market under the symbol “VNRX.” On September 24, 2018, the last reported sale price of our common stock on the NYSE American market was $2.37 per share. As of the date of this prospectus, the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $71,548,670, based on 35,031,225 shares of outstanding common stock, of which approximately 5,946,400 shares were held by affiliates, and a price of $2.46 per share, which was the highest reported closing sale price of our common stock on the NYSE American market in the 60 days prior to September 25, 2018. We have not offered any securities pursuant to General Instruction I.B.6. of Form S-3 during the prior 12-calendar-month period that ends on and includes the date of this prospectus. Pursuant to General Instruction I.B.6. of Form S-3, in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75 million. INVESTING IN THE SECURITIES WE MAY OFFER INVOLVES VARIOUS RISKS. WE STRONGLY RECOMMEND THAT YOU READ CAREFULLY THE RISKS WE DESCRIBE IN THIS PROSPECTUS AS WELL AS IN ANY ACCOMPANYING PROSPECTUS SUPPLEMENT AND THE RISK FACTORS IN OUR MOST CURRENT REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, FOR A XXXXXX UNDERSTANDING OF THE RISKS AND UNCERTAINTIES THAT WE FACE. SEE THE SECTION ENTITLED “RISK FACTORS” ON PAGE 3. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is , 2018 TABLE OF CONTENTS PROSPECTUS Page ABOUT THIS PROSPECTUS 1 PROSPECTUS SUMMARY 2 RISK FACTORS 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION 4 USE OF PROCEEDS 5 GENERAL DESCRIPTION OF SECURITIES 6 DESCRIPTION OF CAPITAL STOCK 7 DESCRIPTION OF WARRANTS 9 DESCRIPTION OF UNITS 10 PLAN OF DISTRIBUTION 11 LEGAL MATTERS 13 EXPERTS 13 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 14 WHERE YOU CAN FIND MORE INFORMATION 15 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Under this shelf registration process, we may from time to time offer and sell any combination of the securities described in this prospectus in one or more offerings with an aggregate initial offering price not to exceed $100,000,000. We have provided to you in this prospectus a general description of the securities we may offer. Each time we sell any of our securities under this prospectus, we will, to the extent required by law, provide a prospectus supplement that will contain specific information about the terms of the offering. We may add, update or change any of the information contained in this prospectus or in any accompanying prospectus supplement we may authorize to be delivered to you. To the extent there is a conflict between the information contained in this prospectus and any accompanying prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date – for example, a document incorporated by reference in this prospectus or any prospectus supplement – the statement in the document having the later date shall modify or supersede such earlier statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. This prospectus, together with any accompanying prospectus supplement, includes all material information relating to an offering pursuant to this registration statement. You should rely only on the information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus, in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date such information is presented. Our business, financial condition, results of operations and prospects may have changed since those respective dates. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. This prospectus and any accompanying prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor does this prospectus and any accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. This prospectus may not be used to offer or sell our securities unless accompanied by a prospectus supplement relating to the offered securities. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered pursuant to this prospectus. The registration statement, including the exhibits, can be read on the SEC’s website or at the SEC’s offices mentioned under the heading “Additional Where You Can Find More Information,.” aboveWe may sell the securities to or through underwriters, dealers or agents or directly to purchasers. Up We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of securities. The prospectus supplement, which we will provide to you each time we offer securities, will set forth the names of any underwriters, dealers or agents involved in the sale of the securities, and any applicable fee, commission or discount arrangements with them. See “Plan of Distribution.” Unless we state otherwise or the context indicates otherwise, references to the “Company”, “VolitionRx”, “we”, “us”, and “our” in this prospectus refer to VolitionRx Limited and its subsidiaries. Our fiscal year ends on December 31 of each calendar year. Nucleosomics®, NuQ®, Nu.QTM and Hypergenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this prospectus are the property of their respective owners. Additionally, unless otherwise specified, all references to “$150,000,000 Common Stock PROSPECTUS SUPPLEMENT” refer to the legal currency of the United States of America.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectusprospectus supplement. The Information in this prospectus supplement supersedes information incorporated by reference is considered to be a part of this prospectus, and information that we file later filed with the SEC will automatically update and supersede information contained in prior to the date of this prospectus and any accompanying prospectus supplement. We incorporate by reference into this prospectus supplement and the registration statement of which this prospectus supplement is a part the information or documents listed below that we have previously filed with the SEC: ● SEC (File No. 001-38542): • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162020, filed with the SEC on March 811, 20172021; ● • our definitive Proxy Statement on Schedule 14A , filed with the SEC on April 29, 2021, as subsequently amended on June 2, 2021 (excluding those portions that are not incorporated by reference into our Annual Report on Form 10-K for the fiscal year ended December 31, 2020); • our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 20172021, June 30, 2021 and September 30, 2021, filed with the SEC on May 12, 2021, August 12, 2021 and November 9, 20172021, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017respectively; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28January 11, 20172021, March June 1, 2021, June 2, 2021, June 30, 20172021, May 26November 9, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 2021 and November 2715, 2017 (other than any portions thereof deemed furnished 2021, in each case to the extent the information in such reports is filed and not filed)furnished; and ● • the description of our common stock contained in our Registration Statement on Form registration statement onForm 8-AA filed with the SEC on June 19, filed on April 14, 20152018, including any amendments thereto or reports filed for the purposes of updating this description. All reports and Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other documents information that we file have “furnished” to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus. We also incorporate by reference into this prospectus supplement all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits that are specifically incorporated by reference into these such documents). You should direct any requests for documents to Xxxxx Life Sciences, Inc., Attn: Xxxx Xxxxxx, Secretary, 0000 Xxxxxxxxx Xxxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, Xxxxxxxxxx 00000; telephone: (000) 000-0000. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement. PROSPECTUS $200,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may request offer up to $200,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. This prospectus provides a copy general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these materials offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. Our common stock is listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol “KZR.” On September 10, 2020, the last reported sale price of our common stock was $4.66 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled “Plan of Distribution” in this prospectus. If any agents or underwriters are involved in the manner sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Additional InformationRisk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page 9 of this prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is September 23, 2020. TABLE OF CONTENTS ABOUT THIS PROSPECTUS i SUMMARY 1 RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 10 USE OF PROCEEDS 12 DESCRIPTION OF CAPITAL STOCK 13 DESCRIPTION OF DEBT SECURITIES 19 DESCRIPTION OF WARRANTS 26 LEGAL OWNERSHIP OF SECURITIES 28 PLAN OF DISTRIBUTION 31 LEGAL MATTERS 33 EXPERTS 33 WHERE YOU CAN FIND MORE INFORMATION 33 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 34 ABOUT THIS PROSPECTUS This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $200,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading “Incorporation of Certain Information by Reference,” abovebefore investing in any of the securities offered. Up to $150,000,000 Common Stock THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading “Where You Can Find More Information.”

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The documents instead of having to repeat the information incorporated by reference is an important part of in this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that and any future filings (including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we have previously filed will make with the SEC: ● SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item 2.02 or Item 7.01 of Form 8-K): • our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, 2015 filed with the SEC on March 8, 20172016, including the information specifically incorporated by reference therein from our definitive proxy statement on Schedule 14A, filed on April 28, 2016; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters period ended March 31, 2017, 2016 filed with the SEC on May 92, 2017, June 30, 2017, 2016; • our current report on Form 8-K/A filed with the SEC on August 9January 13, 2017 2016; and September 30, 2017, filed with • the SEC description of our common stock set forth in our registration statement on November Form 8, 2017; ● our Proxy Statement on Schedule 14A -A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may can request a copy of these materials filings, at no cost, by writing or telephoning us at the following address or telephone number: Aduro Biotech, Inc. 000 Xxxxxxxx Xxx, 3C Berkeley, California 94710 Attn: Investor Relations This prospectus is part of a registration statement we filed with the SEC. That registration statement and the exhibits filed along with the registration statement contain more information about us and the shares in this offering. Because information about documents referred to in this prospectus is not always complete, you should read the manner set forth under full documents which are filed as exhibits to the heading “Additional Information,” aboveregistration statement. Up to You may read and copy the full registration statement and its exhibits at the SEC’s public reference rooms or its website. $150,000,000 100,000,000 Common Stock PROSPECTUS SUPPLEMENTProspectus Xxxxx and Company

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC Securities and Exchange Commission allows us to “incorporate by reference” the information that we file have filed with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important deemed to be part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus, and subsequent information that we file later with the SEC Securities and Exchange Commission will automatically update and supersede information that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and accompanying prospectus to the extent that a statement contained in this prospectus and any supplement or the accompanying prospectus supplementmodifies or replaces that statement. We incorporate by reference the our documents listed below and any future filings made by us with the Securities and Exchange Commission under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act in this prospectus supplement, between the date of this prospectus supplement and the termination of the offering of the securities described in this prospectus supplement. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that we are not deemed “filed” with the Securities and Exchange Commission, including our Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. This prospectus supplement and the accompanying prospectus incorporate by reference the documents set forth below that have previously been filed with the SECSecurities and Exchange Commission: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC Securities and Exchange Commission on March 813, 20172020; ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172020, filed with the SEC Securities and Exchange Commission on May 911, 2017, 2020; • our Quarterly Report on Form 10-Q for the quarter ended June 30, 20172020, filed with the SEC Securities and Exchange Commission on August 96, 2017 2020, and September 30, 2017, as subsequently amended on Form 10-Q/A filed with the SEC Securities and Exchange Commission on November 8August 28, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on Securities and Exchange Commission onJanuary 17, 2020, February 2819, 20172020, February 24, 2020, February 26, 2020, March 5, 2020, March 25, 2020, April 13, 2020, April 16, 2020 (two reports), April 20, 2020, April 22, 2020, April 24, 2020, May 1, 2020, May 8, 2020, May 15, 2020, May 19, 2020, May 22, 2020, June 1, 2020 (two reports), June 2, 2020, June 3, 2020, June 5, 2020, June 26, 2020 (two reports), June 30, 20172020, May 26July 2, 20172020, August 22July 8, 20172020, October July 16, 2020 (two reports), July 17, 20172020, October 19July 20, 20172020, October 24July 21, 2017 2020, and November July 27, 2017 (other than any portions thereof deemed furnished and not filed)2020; and ● • the description of our the Company’s common stock and warrants contained in our Registration Statement on the Form 8-AA filed with the Securities and Exchange Commission on September 17, filed on April 14, 20152018, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we subsequently file with the SEC under Sections pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of this offering, including, but excluding any information furnished to, rather than filed with, the offering of the securities hereunder Securities and Exchange Commission, will also be considered to be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to be part of this prospectus supplement and the accompanying prospectus from the date of the filing of these such reports and documents. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date of this prospectus supplement or the date of the documents incorporated by reference in this prospectus supplement. You may request a free copy of any of the documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address: BioSig Technologies, Inc. Attn: Chief Executive Officer 00 Xxxxxx Xxxx, 0xx Xxxxx Xxxxxxxx, Xxxxxxxxxxx 00000 (000) 000-0000 You may also access the documents incorporated by reference in this prospectus through our website at xxx.xxxxxxxxxx.xxx. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. WHERE YOU CAN FIND MORE INFORMATION We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and will supersede the information herein; providedin accordance therewith file annual, however, that all quarterly and current reports, exhibits proxy statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Securities and Exchange Commission. The address of the Securities and Exchange Commission’s website is xxx.xxx.xxx. We make available free of charge on or through our website at xxx.xxxxxxxxxx.xxx, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Securities and Exchange Commission. We have filed with the Securities and Exchange Commission a registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement for free at xxx.xxx.xxx. The registration statement and the documents referred to below under “Incorporation of Certain Information By Reference” are also available on our website, xxx.xxxxxxxxxx.xxx. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus. PROSPECTUS BioSig Technologies, Inc. $75,000,000 Common Stock Preferred Stock Warrants Units We may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $75,000,000. We will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. These securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. See “furnishPlan of Distribution.” Our common stock is listed on the Nasdaq Capital Market under the symbol “BSGM.” On March 21, 2019, the last reported sale price of our common stock as reported on the Nasdaq Capital Market was $6.00 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision. We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities exchange. Effective as of 5:00 pm Eastern Time on September 11, 2018, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of the SEC will not be considered issued and outstanding shares of our common stock, at a ratio of one share for 2.5 shares. All share and per share prices in this prospectus have been adjusted to reflect the reverse stock split. You should carefully read this prospectus, any prospectus supplement relating to any specific offering of securities, and all information incorporated by reference herein and therein. Investing in our securities involves a high degree of risk. These risks are discussed in this prospectus under “Risk Factors” beginning on page 4 and in the documents incorporated by reference into this prospectus. We undertake to provide without charge to each person (including Neither the Securities and Exchange Commission nor any beneficial owner) who receives a copy state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. This prospectus is dated March 29, 2019, as amended by the prospectus supplement relating to our Description of Capital Stock dated August 28, 2020. TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS ii PROSPECTUS SUMMARY 1 RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5 USE OF PROCEEDS 6 DESCRIPTION OF CAPITAL STOCK 7 DESCRIPTION OF WARRANTS 13 DESCRIPTION OF UNITS 14 PLAN OF DISTRIBUTION 15 LEGAL MATTERS 17 EXPERTS 17 WHERE YOU CAN FIND MORE INFORMATION 17 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 18 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission using a “shelf” registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $75,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also add, update or change in a prospectus supplement any information contained in this prospectus. To the extent any statement made in a prospectus supplement or a document incorporated by reference herein after the date hereof is inconsistent with the statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement or the incorporated document. The prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the securities. You should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be relied upon written as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or oral request, a copy solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the preceding information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENThave changed since that date.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC Securities and Exchange Commission allows us to “incorporate by reference” the information that we file have filed with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated we incorporate by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and later information that we file later with the SEC Securities and Exchange Commission will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below that and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we have previously filed file with the SECSecurities and Exchange Commission pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior to the termination of the offering: ● our • Our Annual Report on Form 10-K for the fiscal year ended December 31, 20162018, filed with the SEC Securities and Exchange Commission on March 815, 20172019; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Our Current Reports on Form 8-K filed with the SEC on February 28onFebruary 11, 20172019, March 306, 20172019, May 26and March 14, 2017, August 22, 2017, October 2019; and • The description of the Company’s common stock and warrants contained in theForm 8-A filed with the SEC on September 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 20152018, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with filings filed by us pursuant to the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of the initial filing of this prospectus but before registration statement and prior to the termination effectiveness of the offering such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of the securities hereunder will Form 8-K) shall also be considered deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede prospectus. You should rely only on the information herein; provided, however, that all reports, exhibits and other information that we “furnish” incorporated by reference or provided in this prospectus. We have not authorized anyone else to the SEC will not be considered provide you with different information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus. We undertake to will provide without charge to each person (including any beneficial owner) who receives to whom a copy of this prospectusprospectus is delivered, upon written or oral request, a copy of any or all of the preceding reports or documents that are have been incorporated by reference in this prospectus but not delivered with this prospectus (other than exhibitsan exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at: BioSig Technologies, Inc. Attn: Chief Executive Officer 00000 Xxxxxxxx Xxxx., Xxxxx 000 Xxx Xxxxxxx, XX 00000 (000) 000-0000 You may also access the exhibits are specifically documents incorporated by reference into these documents)in this prospectus through our website at xxx.xxxxxxxxxx.xxx. You may request Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a copy of these materials in the manner set forth under the heading “Additional Information,” abovepart. 18 Up to $150,000,000 45,000,000 Common Stock PROSPECTUS SUPPLEMENTSUPPLEMENT Jefferies

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference information that we file with it into this prospectus, which document. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectusanother document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectusdocument, and except for any information superseded by information that we file later with the SEC will automatically update and supersede information contained is included directly in this prospectus and any accompanying prospectus supplementor incorporated by reference subsequent to the date of this prospectus. We incorporate by reference the following documents listed below or information that we have previously filed with the SEC: ● • our 2019 Annual Report on Form 1020-K F for the fiscal year ended December 31, 20162019, or the Annual Report; • our Forms 6-K filed with the SEC on March 82, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 312020, 2017May 21, filed with the SEC on May 9, 2017, 2020 and June 30, 2017, filed with 2020; and • the SEC description of our common shares contained in our registration statement on August 9, 2017 and September 30, 2017, Form 8-A filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 287, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● as updated by the description of our common stock contained in our Registration Statement on Form 8-A, shares filed on April 14, 2015as Exhibit 2.4 to the Annual Report, including any amendments thereto or reports filed for the purposes of updating this descriptionsupplements thereto. All annual reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of pursuant to the Exchange Act on Form 20-F after the date of this prospectus but before the and prior to termination or expiration of the offering of the securities hereunder will also this registration statement shall be considered to be deemed incorporated by reference into this prospectus and to be part hereof from the date of the filing of these reports and such documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” . We may incorporate by reference any Form 6-K subsequently submitted to the SEC will not be considered by identifying in such Form 6-K that it is being incorporated by reference into this prospectus. We undertake to provide Documents incorporated by reference in this prospectus are available from us without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding excluding any exhibits to those documents that are incorporated by reference (other than exhibits, unless the exhibits are not specifically incorporated by reference into these those documents). You may request a copy of these materials can obtain documents incorporated by reference in the manner set forth under the heading “Additional Information,” abovethis document by requesting them from us in writing at Xxxxxxxxxx Xxx. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENT0, 00000 Xxxx, Xxxxxxx or via telephone at (+00) 0000 000 000. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information filed by us electronically at xxxx://xxx.xxx.xxx.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The Information in this prospectus supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectus, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementprospectus. We also incorporate by reference into this prospectus the documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed and any future filings made by us with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on (other than current reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement, and (ii) after the effectiveness of the registration statement but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated covered by reference into this prospectus from prospectus: • our Annual Report on Form 10-K for the date year ended December 31, 2019 filed with the SEC on March 10, 2020; • our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2020 and June 30, 2020 filed with the SEC on June 18, 2020 and August 13, 2020, respectively; • our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on January 30, 2020, March 2, 2020, April 6, 2020, April 20, 2020, April 24, 2020, May 5, 2020, May 14, 2020, June 19, 2020, July 2, 2020, August 14, 2020, August 24, 2020 and August 26, 2020; and • the description of our common stock which is registered under Section 12 of the filing Exchange Act, in our registration statement on Form 8-A, filed on August 17, 2018, including any amendment or reports filed for the purposes of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into updating this prospectusdescription. We undertake to provide will furnish without charge to each person (person, including any beneficial owner) who receives a copy of , to whom this prospectusprospectus is delivered, upon written or oral request, a copy of all any document incorporated by reference. You should direct any requests for documents to Bionano Genomics, Inc. 0000 Xxxxx Xxxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx, Xxxxxxxxxx 00000; telephone: (000) 000-0000. In accordance with Rule 412 of the preceding documents that are Securities Act, any statement contained in a document incorporated by reference (herein shall be deemed modified or superseded to the extent that a statement contained herein or in any other than exhibits, unless the exhibits are specifically subsequently filed document which also is or is deemed to be incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTherein modifies or supersedes such statement.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 8May 29, 20172020; ● our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172020, filed with the SEC on May 9June 24, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 20172020; ● our Current Reports on Form 8-K filed with the SEC on February 2827, 20172020, March 30, 20172020, May 2614, 20172020 and June 12, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2020 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock stock, par value $0.0001 per share, contained in our Registration Statement on Form 8-A, A filed on April 14August 12, 20152013, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial registration statement and prior to effectiveness of the registration statement, and after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. VYANT BIO, INC. Up to $150,000,000 14,500,000 of Common Stock PROSPECTUS SUPPLEMENT

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference much of the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information incorporated that we incorporate by reference is an important part of in this prospectus. The information incorporated by reference prospectus supplement is considered to be a part of this prospectus, and information that prospectus supplement. Because we file later are incorporating by reference future filings with the SEC will automatically update SEC, this prospectus supplement is continually updated and those future filings may modify or supersede some of the information contained included or incorporated by reference in this prospectus and any accompanying prospectus supplement. We This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement incorporates by reference the documents listed below that and any future filings we have previously filed make with the SECSEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished pursuant to Items 2.02 or 7.01 of any Current Report on Form 8-K and, except as may be noted in any such Form 8-K, exhibits filed on such form that are related to such information), until the offering of the securities under the registration statement of which this prospectus supplement forms a part is terminated or completed: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, as filed with the SEC on March 8February 24, 20172022; ● • our Quarterly Reports Definitive Proxy Statement on Form 10-Q Schedule 14A for the fiscal quarters ended March 31our 2022 Annual Meeting of Stockholders, 2017, as filed with the SEC on May 92, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● • the description of our common stock contained in our the Registration Statement on Form 8-AA relating thereto, as filed with the SEC on April 14March 17, 20152021, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other Any documents that we file with the SEC under Sections pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before supplement and prior to the termination of the offering of the our securities hereunder to which this prospectus supplement relates will also automatically be considered deemed to be incorporated by reference into this prospectus supplement and to be part hereof from the date of the filing of these reports and those documents, and will supersede the information herein; provided. We are not, however, incorporating by reference any documents or portions thereof that all reportsare not deemed “filed” with the SEC, including any information furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. Any statements in any such future filings will automatically be deemed to modify and other supersede any information in any document we previously filed with the SEC that we “furnish” is incorporated or deemed to be incorporated herein by reference to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written extent that statements in the later filed document modify or oral request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically incorporated by reference into these documents)replace such earlier statements. You may can request a copy of these materials filings, at no cost, by writing or telephoning us at the following address or telephone number: Edgewise Therapeutics, Inc. 0000 Xxxxxxxx Xxx. Boulder, CO 80303 000-000-0000 The information accessible through any website referred to in the manner set forth under the heading “Additional Information,” abovethis prospectus supplement or any document incorporated herein is not, and should not be deemed to be, a part of this prospectus supplement. Up to PROSPECTUS Edgewise Therapeutics, Inc. $150,000,000 Common Stock PROSPECTUS SUPPLEMENT400,000,000

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC Securities and Exchange Commission allows us to “incorporate by reference” the information that we file have filed with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important deemed to be part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus, and subsequent information that we file later with the SEC Securities and Exchange Commission will automatically update and supersede information that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and accompanying prospectus to the extent that a statement contained in this prospectus and any supplement or the accompanying prospectus supplementmodifies or replaces that statement. We incorporate by reference the our documents listed below and any future filings made by us with the Securities and Exchange Commission under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act in this prospectus supplement, between the date of this prospectus supplement and the termination of the offering of the securities described in this prospectus supplement. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that we are not deemed “filed” with the Securities and Exchange Commission, including our Compensation Committee report and performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K. This prospectus supplement and the accompanying prospectus incorporate by reference the documents set forth below that have previously been filed with the SECSecurities and Exchange Commission: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 20162021, filed with the SEC Securities and Exchange Commission onMarch 31, 2022 (as amended on March 8Form 10-K/A on May 2, 20172022); ● • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 20172022, filed with the SEC on May 9onMay 16, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172022; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February Securities and Exchange Commission onMarch 22, 2022, March 24, 2022, April 28, 20172022 and May 2, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2022; and ● • the description of our the Company’s common stock and warrants contained in our Registration Statement on the Form 8-AA filed with the Securities and Exchange Commission on September 17, filed 2018, as amended by Exhibit 4.1 to our Annual Report on April 14Form 10-K for the fiscal year ended December 31, 20152021, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we subsequently file with the SEC under Sections pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before prior to the termination of this offering, including, but excluding any information furnished to, rather than filed with, the offering of the securities hereunder Securities and Exchange Commission, will also be considered to be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to be part of this prospectus supplement and the accompanying prospectus from the date of the filing of these such reports and documents, and will supersede . You should rely only on the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into or provided in this prospectus. We undertake have not authorized anyone else to provide without charge to each person (including you with different information. You should not assume that the information in this prospectus supplement is accurate as of any beneficial owner) who receives a copy date other than the date of this prospectus, upon written prospectus supplement or oral request, a copy of all the date of the preceding documents that are incorporated by reference in this prospectus supplement. You may request a free copy of any of the documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits, unless the exhibits they are specifically incorporated by reference into in the documents) by writing or telephoning us at the following address: BioSig Technologies, Inc. Attn: Chief Executive Officer 00 Xxxxxx Xxxxx Xxxx, 0xx Xxxxx Xxxxxxxx, Xxxxxxxxxxx 00000 (000) 000-0000 You may also access the documents incorporated by reference in this prospectus through our website at xxx.xxxxxx.xxx. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. WHERE YOU CAN FIND MORE INFORMATION We are subject to the informational requirements of the Exchange Act, and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Securities and Exchange Commission. The address of the Securities and Exchange Commission’s website is xxx.xxx.xxx. We make available free of charge on or through our website at xxx.xxxxxx.xxx, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Securities and Exchange Commission. We have filed with the Securities and Exchange Commission a registration statement under the Securities Act, relating to the offering of these documents)securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You may request can obtain a copy of these materials the registration statement for free at xxx.xxx.xxx. The registration statement and the documents referred to below under “Incorporation of Certain Information By Reference” are also available on our website, xxx.xxxxxx.xxx. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus. Prospectus $75,000,000 Common Stock Preferred Stock Warrants Units We may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus, up to an aggregate amount of $75,000,000. We will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. These securities may be offered and sold in the manner set forth same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation and any over-allotment options held by them will be described in the applicable prospectus supplement. See “Plan of Distribution.” Our common stock is listed on The Nasdaq Capital Market under the heading symbol “Additional InformationBSGM.” On December 30, 2020, the last reported sale price of our common stock was $4.13 per share as reported on The Nasdaq Capital Market. We recommend that you obtain current market quotations for our common stock prior to making an investment decision. We will provide information in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities exchange. You should carefully read this prospectus, any prospectus supplement relating to any specific offering of securities, and all information incorporated by reference herein and therein. Investing in our securities involves a high degree of risk. These risks are discussed in this prospectus under “Risk Factors” beginning on page 6and in the documents incorporated by reference in this prospectus. Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The date of this prospectus is January 12, 2021 TABLE OF CONTENTS Page About This Prospectus ii Cautionary Statement Regarding Forward-Looking Statements 1 Prospectus Summary 3 Risk Factors 6 Use of Proceeds 7 Description of Capital Stock 8 Description of Warrants 12 Description of Units 14 Plan of Distribution 15 Legal Matters 18 Experts 18 Where You Can Find More Information 18 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the SEC using a “shelf” registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $75,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent, information in this prospectus is superseded by the information in the prospectus supplement. The prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the securities. You should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by reference in this prospectus, any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may have changed since that date. All references in this prospectus to “BioSig,” above. Up the “Company,” “we,” “us,” “our,” or similar terms refer to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTBioSig Technologies, Inc. and its subsidiaries taken as a whole, except where the context otherwise requires or as otherwise indicated.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001-37894. The information documents incorporated by reference is considered to be a part of into this prospectus contain important information that you should read about us. The following documents are incorporated by reference into this prospectus, and information that we file later : • our Current Reports on Form 8-K filed with the SEC will automatically update on M arch 10, 2020, M ay 4, 2020, M ay 27, 2020, J uly 27, 2020, A ugust 4, 2020 and supersede A ugust 5, 2020 (in each case, except for the information contained furnished under Items 2.02 or 7.01 in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously Current Report on Form 8-K); • our Quarterly Reports on Form 10-Q filed with the SEC: ● SEC on M ay 6, 2020 and A ugust 5, 2020; • our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, 2019 filed with the SEC on March 8M arch 13, 20172020; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● • the description of our common stock contained in our Registration Statement on Form 8-A, A initially filed on April 14S eptember 26, 20152016, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All ; and • all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination or completion of the offering of securities under this prospectus shall be deemed to be incorporated by reference in this prospectus and to be a part hereof from the date of filing such reports and other documents. We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8-K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits which are specifically incorporated by reference into these such documents). You may request Requests should be directed to: Fulgent Genetics, Inc., Attn: Investor Relations, 0000 Xxxxx Xxxxx Xxxxxx, Suite 205, Temple City, California 91780, telephone: (000) 000-0000. Any statement contained herein or in a copy document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of these materials the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTstatement.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with it into this prospectusprospectus supplement which has been previously filed with the SEC, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information incorporated by reference is an important deemed to be part of this prospectus. The prospectus supplement, except for any information superseded by information included or subsequently incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference have filed the documents listed below that we have previously filed with the SEC: ● SEC under the Exchange Act, and these documents are incorporated herein by reference (except to the extent such information is furnished): • our Annual Report on Form 10-–K for the fiscal year ended December 31, 20162022, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2023; and ● • the description of our Class A common stock contained in our Registration Statement on Form registration statement onForm 8-AA filed with the SEC on January 31, filed on April 14, 20152019, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All reports and other documents that we file (but not those that we furnish) with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus but before supplement and prior to the termination of the offering of the securities hereunder shares of Class A common stock hereby will also be considered deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, supplement and will automatically update and supersede the information herein; providedin this prospectus supplement and any previously filed document. We will provide to each person, howeverincluding any beneficial owner, that to whom a copy of this prospectus supplement is delivered, a copy of any or all reports, exhibits and other of the information that we “furnish” has been incorporated by reference in this prospectus supplement but not delivered with this prospectus supplement (other than the exhibits to such documents which are not specifically incorporated by reference herein). We will provide this information at no cost to the SEC will requester upon written or oral request to: Luminar Technologies, Inc. 0000 Xxxxxxxxx Xxxxx, Xxxxx 000 Orlando, Florida 32826 Telephone: (000) 000-0000 You may also access these documents, free of charge on the SEC’s website at xxx.xxx.xxx or on the “Investors” page of our website at xxxxxxxxxxx.xxx. Information contained on our website is not be considered incorporated by reference into this prospectus, and you should not consider any information on, or that can be accessed from, our website as part of this prospectus or any accompanying prospectus supplement. PROSPECTUS $204,000,000 Class A Common Stock Preferred Stock Debt Securities Warrants Units From time to time, we may offer, issue and sell up to $204,000,000 of any combination of the securities described in this prospectus in one or more offerings. We undertake to provide without charge to each person (may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any beneficial owner) who receives applicable antidilution provisions. This prospectus provides a copy general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, upon written or oral requestthe applicable prospectus supplement and any related free writing prospectus, a copy of all as well as any documents incorporated by reference, before you invest in any of the preceding securities being offered. This prospectus may not be used to sell our securities unless accompanied by a prospectus supplement. The prospectus supplement or any related free writing prospectus may also add to, update, supplement or clarify information contained in this prospectus. Our Class A common stock is traded on The Nasdaq Global Select Market under the symbol “LAZR”. The last reported sales price of our Class A common stock on The Nasdaq Global Select Market on January 28, 2022 was $13.03 per share. We may offer and sell our securities to or through one or more agents, underwriters, dealers or other third parties or directly to one or more purchasers on a continuous or delayed basis. If agents, underwriters or dealers are used to sell our securities, we will name them and describe their compensation in a prospectus supplement. The price to the public of our securities and the net proceeds we expect to receive from the sale of such securities will also be set forth in a prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading “Risk Factors” on page 3 of this prospectus as well as those contained in the applicable prospectus supplement and any related free writing prospectus, and in the other documents that are incorporated by reference (other than exhibitsinto this prospectus or the applicable prospectus supplement. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is February 3, unless the exhibits are specifically incorporated by reference into these documents)2022. You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS SUPPLEMENTii COMPANY OVERVIEW 1 CORPORATE INFORMATION 2 RISK FACTORS 3 CAUTIONARY NOTE REGARDING FORWARD–LOOKING STATEMENTS 4 USE OF PROCEEDS 6 DESCRIPTION OF OUR CAPITAL STOCK 7 DESCRIPTION OF OUR DEBT SECURITIES 14 DESCRIPTION OF OUR WARRANTS 15 DESCRIPTION OF OUR UNITS 16 PLAN OF DISTRIBUTION 17 LEGAL MATTERS 19 EXPERTS 19 WHERE YOU CAN FIND ADDITIONAL INFORMATION 19

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “"incorporate by reference” " information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus supplement and the accompanying prospectus. The Information in this prospectus supplement supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectusprospectus supplement, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference into this prospectus supplement and the registration statement of which this prospectus is a part the information or documents listed below that we have previously filed with the SEC: ● SEC (Commission File No. 001-36644): ▪ our Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 8February 27, 20172020 ; ● ▪ the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2019 from our definitive proxy statement on Schedule 14A, filed with the SEC on April 1, 2020; ▪ our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarterly period ended March 31, 20172020, filed with the SEC on May 95, 2017, 2020 ; ▪ our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 20172020, filed with the SEC on August 94, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020 ; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● ▪ our Current Reports Report on Form 8-K filed with the SEC on February 28May 15, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2020 ; and ● ▪ the description of our common stock contained stock, which is registered under Section 12 of the Exchange Act in our Registration Statement registration statement on Form 8-A, filed with the SEC on April 14October 3, 20152000, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and other documents exhibits filed on such form that we file are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act Act, including those made after the date of the initial filing of the registration statement of which this prospectus but before supplement and the accompanying prospectus is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities hereunder shares of our common stock made by this prospectus supplement and the accompanying prospectus and will also become a part of this prospectus supplement from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement and the accompanying prospectus. Any statements in any such future filings will automatically be considered deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference into to the extent that statements in the later filed document modify or replace such earlier statements. You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: Rigel Pharmaceuticals, Inc. 0000 Xxxxxxxx Xxxxxxxxx South San Francisco, CA 00000 (000) 000-0000 Table of Contents Prospectus $200,000,000 Common Stock Preferred Stock Debt Securities Warrants From time to time, we may offer and sell up to an aggregate amount of $200,000,000 of any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. Our common stock is listed on The Nasdaq Global Market under the trading symbol "RIGL." On March 8, 2018, the last reported sale price of our common stock was $4.45 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The Nasdaq Global Market or other securities exchange of the securities covered by the applicable prospectus supplement. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" on page 5 of this prospectus from and any similar section contained in the date of the filing of these reports applicable prospectus supplement and documentsin any free writing prospectuses we have authorized for use in connection with a specific offering, and will supersede under similar headings in the information herein; provided, however, documents that all reports, exhibits and other information that we “furnish” to the SEC will not be considered are incorporated by reference into this prospectus. This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is April 2, 2018. TABLE OF CONTENTS ABOUT THIS PROSPECTUS ii PROSPECTUS SUMMARY 1 RISK FACTORS 5 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5 USE OF PROCEEDS 6 RATIO OF EARNINGS TO FIXED CHARGES 6 DESCRIPTION OF CAPITAL STOCK 7 DESCRIPTION OF DEBT SECURITIES 11 DESCRIPTION OF WARRANTS 18 LEGAL OWNERSHIP OF SECURITIES 20 PLAN OF DISTRIBUTION 24 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND ADDITIONAL INFORMATION 26 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 26 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, using a "shelf" registration process. Under this shelf registration statement, we may sell from time to time in one or more offerings up to a total dollar amount of $200,000,000 of common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination with other securities as described in this prospectus. Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We undertake may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also add, update or change in a prospectus supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under "Where You Can Find Additional Information," before buying any of the securities being offered. This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. You should rely only on the information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide without charge you with different or additional information. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus, any applicable supplement to each this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person (including to whom it is unlawful to make such offer or solicitation in such jurisdiction. The information appearing in this prospectus, any beneficial owner) who receives a copy applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, upon written any applicable prospectus supplement or oral requestany related free writing prospectus, or any sale of a copy security. Our business, financial condition, results of all operations and prospects may have changed since those dates. This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the preceding market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading "Risk Factors" contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference (other than exhibitsinto this prospectus. Accordingly, unless investors should not place undue reliance on this information. This prospectus contains summaries of certain provisions contained in some of the exhibits documents described herein, but reference is made to the actual documents for complete information. All of the summaries are specifically qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference into these documents). You as exhibits to the registration statement of which this prospectus is a part, and you may request a copy obtain copies of these materials in the manner set forth those documents as described below under the heading “section entitled "Where You Can Find Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENT."

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference the information that and reports we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those these documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectusprospectus supplement, and information that we file later after the date hereof with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementalready incorporated by reference. We incorporate are incorporating by reference the documents listed below that we have previously below: ∎ Annual Report on F orm 10-K for the year ended December 31, 2020 filed with the SEC: ● SEC on February 12, 2021; ∎ The information specifically incorporated by reference in our Annual Report on Form 10-K for the fiscal year ended December 31, 20162020, which was filed with the SEC on March 8February 12, 20172021, from our Definitive Proxy Statement on S chedule 14A relating to our 2021 Annual Meeting of Stockholders, which was filed with the SEC on April 29, 2021; ● our ∎ Quarterly Reports Report on Form F orm 10-Q for the fiscal quarters quarter ended March 31, 20172021, filed with the SEC on May 95, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172021; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our ∎ Current Reports on Form 8-K filed with the SEC on February 28J anuary 8, 20172021, March 30J anuary 21, 20172021 and A pril 16, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed)2021; and ● the ∎ The description of our common stock contained in our Registration Statement registration statement on Form F orm 8-AA (File No. 001-36276) filed with the SEC on January 24, filed on April 14, 20152014, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All reports and other documents that we file with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act shall be deemed incorporated by reference in this prospectus supplement and to be a part of this prospectus supplement from the date of filing of those documents, with the exception of any portion of any report or document that is not deemed “filed” under such provisions on or after the date of this prospectus but before supplement, until the termination earlier of the offering date on which: (1) all of the securities registered hereunder have been sold; or (2) the registration statement of which this prospectus supplement is a part has been withdrawn. Under no circumstances will also any information filed under current items 2.02 or 7.01 of Form 8-K be considered to be deemed incorporated herein by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” unless such Form 8-K expressly provides to the SEC contrary. Upon written or oral request, we will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives to whom a copy of this prospectus, upon written or oral request, the prospectus supplement is delivered a copy of all of the preceding documents that are incorporated by reference herein (other than exhibits, exhibits to such documents unless the such exhibits are specifically incorporated by reference into these documentsherein). You may request a copy of these materials in filings, at no cost, by writing, calling or emailing us at the manner contact information set forth under below. We have authorized no one to provide you with any information that differs from that contained in this prospectus supplement. Accordingly, we take no responsibility for any other information that others may give you. You should not assume that the heading “Additional Information,” aboveinformation in this prospectus supplement is accurate as of any date other than the date of the front cover of this prospectus supplement. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTUltragenyx Pharmaceutical Inc. 00 Xxxxxxxx Xxxxx Novato, California 94949 (000) 000-0000 PROSPECTUS

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” into this prospectus supplement the information that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated we incorporate by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectusprospectus supplement, and later information that we file later with the SEC will automatically update and supersede information contained in some of this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), including filings made after the date of the initial registration statement, until we sell all of the shares covered by this prospectus supplement or the sale of shares by us pursuant to this prospectus supplement is terminated. In no event, however, will any of the information that we have previously filed with furnish to, pursuant to Item 2.02 or Item 7.01 of any Current Report on Form 8-K (including exhibits related thereto) or other applicable SEC rules, rather than file with, the SECSEC be incorporated by reference or otherwise be included herein, unless such information is expressly incorporated herein by a reference in such furnished Current Report on Form 8-K or other furnished document. The documents we incorporate by reference are: ● • our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 830, 2017; ● • the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2016 from our definitive proxy statement relating to our 2017 annual meeting of stockholders, which was filed on April 24, 2017; • our Quarterly Reports Report on Form 10-Q for the fiscal quarters quarter ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 815, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K or Form 8-K/A filed with the SEC on February 28January 25, 2017, March 30February 13, 2017, February 14, 2017, February 17, 2017, April 6, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27June 2, 2017 (other than any portions thereof deemed furnished each to the extent filed and not filedfurnished); and ● • the description of our common stock contained in our Registration Statement the registration statement on Form 8-AA (File no. 001-36332), filed on April 14March 4, 20152014, including any and all amendments thereto or and reports filed for the purposes of updating this such description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 Any statement contained in a document incorporated or 15(d) of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder will also be considered deemed to be incorporated by reference into this prospectus from the date supplement will be deemed to be modified or superseded for purposes of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” this prospectus supplement to the SEC extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be considered deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. We will provide each person to whom a prospectus supplement is delivered a copy of all of the information that has been incorporated by reference in this prospectus supplement but not delivered with the prospectus supplement. You may obtain copies of these filings, at no cost, through the “Investor Relations” section of our website (xxx.xxxxxxx.xxx) and you may request a copy of these filings (other than an exhibit to any filing unless we have specifically incorporated that exhibit by reference into the filing), at no cost, by writing or telephoning us at the following address: 000 Xxxxxxxx Xxxxxx, Suite 320 Lexington, MA 02421 (000) 000-0000 Information on, or that can be accessed through, our website is not incorporated into this prospectus or other securities filings and is not a part of these filings. PROSPECTUS $100,000,000 Preferred Stock Common Stock Debt Securities Warrants From time to time, we may offer and sell shares of preferred stock, common stock, debt securities or warrants to purchase debt securities, preferred stock, common stock or any combination of these securities, either separately or in units, in one or more offerings in amounts, at prices and on terms that we will determine at the time of the offering. The debt securities and warrants may be convertible into or exercisable or exchangeable for preferred stock, common stock or debt securities and the preferred stock may be convertible into or exchangeable for common stock. The aggregate initial offering price of all securities sold by us under this prospectus will not exceed $100,000,000. Each time we offer securities, we will provide you with specific terms of the securities offered in supplements to this prospectus. The prospectus supplement may also add, update or change information contained in this prospectus. You should read this prospectus, the information incorporated by reference in this prospectus, any applicable prospectus supplement and the additional information described below under the heading “Where You Can Find More Information” carefully before you invest in any securities. The securities offered by this prospectus may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or dealers. We will set forth the names of any underwriters or agents in an accompanying prospectus supplement. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution.” The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. Our common stock is listed on The NASDAQ Capital Market under the symbol “ALDX”. The last reported sale price of our common stock on August 21, 2015 was $7.41 per share. INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISKS. SEE “RISK FACTORS” ON PAGE 6 OF THIS PROSPECTUS AND IN THE OTHER DOCUMENTS INCORPORATED BY REFERENCE IN THIS PROSPECTUS AND THE APPLICABLE PROSPECTUS SUPPLEMENT TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING OUR SECURITIES. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus or any accompanying prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is September 1, 2015. TABLE OF CONTENTS Page ABOUT THIS PROSPECTUS 1 WHERE YOU CAN FIND MORE INFORMATION 1 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 THE COMPANY 5 OUR CORPORATE INFORMATION 5 RISK FACTORS 6 DESCRIPTION OF SECURITIES 38 USE OF PROCEEDS 51 RATIO OF FIXED CHARGES AND PREFERENCE DIVIDENDS TO EARNINGS 51 DIVIDEND POLICY 51 PLAN OF DISTRIBUTION 51 LEGAL MATTERS 52 EXPERTS 53 You should rely only on the information contained or incorporated by reference in this prospectus or any applicable prospectus supplement. We have not authorized anyone to provide you with information in addition to or different from that contained in this prospectus or any applicable prospectus supplement. We will be offering to sell, and seeking offers to buy, the shares only in jurisdictions whether offers and sales are permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date on the front of those documents. Unless the context otherwise requires, throughout this prospectus and any applicable prospectus supplement, the words “Aldeyra” “we,” “us,” the “registrant” or the “company” refer to Aldeyra Therapeutics, Inc.; the term “securities” refers collectively to our preferred stock, common stock, debt securities or warrants to purchase preferred stock, common stock or debt securities, or any combination of the foregoing securities. ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration process. Using this process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offering transactions up to a total dollar amount of $100,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we sell any securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the specific terms of that particular offering. Each such prospectus supplement may also add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. We undertake To the extent that any statements that we make in a prospectus supplement are inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement. This prospectus, together with the applicable prospectus supplements and the documents incorporated by reference into this prospectus, includes all material information relating to provide without charge to each person (including any beneficial owner) who receives a copy the offering of the securities described in this prospectus. The information contained in this prospectus is accurate only as of the date of this prospectus, upon written regardless of the time of delivery of this prospectus or oral requestany sales of securities. To obtain additional information that may be important to you, you should read the exhibits filed by us with the registration statement of which this prospectus is a part or our other filings with the SEC. You should read this prospectus, any applicable prospectus supplement and the additional information described below under “Where You Can Find More Information” before making any investment decision with respect to the securities offered hereby. WHERE YOU CAN FIND MORE INFORMATION We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits, schedules and undertakings set forth in the registration statement, as permitted by the SEC. For further information pertaining to us and the securities offered in this prospectus, reference is made to that registration statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents or provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where a copy of all the document has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete description of the preceding documents matters involved. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings can be read and copied at the SEC’s Public Reference Room at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. The public may obtain information on the operation of the public reference room by calling the SEC at 0-000-XXX-0000. Also, the SEC maintains a website at xxx.xxx.xxx that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including us. Our common stock is listed on the NASDAQ Capital Market under the symbol “ALDX.” General information about our company, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as any amendments and exhibits to those reports, are available free of charge through our website at xxx.xxxxxxx.xxx as soon as reasonably practicable after we file them with, or furnish them to, the SEC. Information on, or than can be accessed through, our website is not incorporated by reference (into this prospectus or other than exhibits, unless the exhibits are specifically incorporated by reference into these documents). You may request securities filings and is not a copy part of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTfilings.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. Assertio files annual, quarterly and current reports, proxy statements and other information with the SEC. Assertio’s SEC filings are available to the public from commercial retrieval services and are available at the Internet website maintained by the SEC at xxx.xxx.xxx. The SEC allows us to “incorporate filings are also available on Assertio’s website at xxxx://xxx.xxxxxxxxxx.xxx. The information contained in Assertio’s website does not constitute a part of this Joint Proxy Statement/Prospectus. Assertio is ‘‘incorporating by reference” information that we file with it ’’ into this prospectusJoint Proxy Statement/Prospectus the information in certain documents that Xxxxxxxx previously filed with the SEC, which means that we Assertio can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectusJoint Proxy Statement/Prospectus. The Any reports filed by Assertio on or after the date of this Joint Proxy Statement/Prospectus supersede any information contained, or incorporated by reference, herein. Assertio incorporates by reference is considered to be a part of in this prospectus, Joint Proxy Statement/Prospectus the documents listed below and information any filings on or after the date hereof that we file later Assertio makes with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the ‘‘Exchange Act’’), excluding any information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K. The future filings with the SEC made by Assertio will automatically update and supersede any inconsistent information contained in this prospectus Joint Proxy Statement/Prospectus and any accompanying prospectus supplementearlier dated incorporated document. We incorporate by reference the documents listed below that we have previously filed with the SEC: ● our • Assertio’s Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 20172020; ● our and • Assertio’s Current Reports on Form 8-K filed with the SEC on January 13, 2020, January 16, 2020, February 287, 20172020, February 13, 2020, February 20, 2020, and March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than 2020. This Joint Proxy Statement/Prospectus does not incorporate by reference any documents or portions thereof or exhibits thereto specifically listed above that are deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 2015, including any amendments thereto or reports filed for the purposes of updating this description. All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 SEC. You may also request a copy of any or 15(d) all of the Exchange Act after the date of this prospectus but before the termination of the offering of the securities hereunder documents referred to above that have been or will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral request, a copy of all of the preceding documents that are incorporated by reference Joint Proxy Statement/Prospectus (other than exhibits, an exhibit to a filing unless the exhibits are that exhibit is specifically incorporated by reference into these documents)that filing) at no cost, by writing to Assertio at 000 Xxxxx Xxxxxxxx Xxxx, Suite 300, Lake Forest, Illinois, 60045, and Assertio’s telephone number is (000) 000-0000. You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTQUESTIONS AND ANSWERS ABOUT THE PROPOSALS AND STOCKHOLDER MEETINGS General Questions and Answers for Assertio Stockholders and Xxxx Stockholders

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows rules allow us to “incorporate by reference” the information that we file with it into this prospectusthe SEC, which means that we can disclose important information to you by referring you to those documentsdocuments filed separately with the SEC. The information incorporated by reference is an important part of in this prospectus. The information incorporated by reference prospectus supplement and the accompanying prospectus is considered to be a part of this prospectus supplement and the accompanying prospectus, and the information that we file later subsequently with the SEC prior to the completion of this offering will automatically update and supersede information contained in such information. We previously filed the following documents with the SEC and such filings are incorporated by reference into this prospectus supplement and any the accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SECprospectus: ● our • Annual Report on Form 10-K for the fiscal year ended December 31, 20162019, filed February 19, 2020 (including portions of our definitive Proxy Statement for the 2020 Annual Meeting of Stockholders, filed with the SEC on March 8, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 2020 that are specifically incorporated therein by reference); and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-AK, filed on April 14January 15, 20152020 and February 20, including any amendments thereto or reports filed for the purposes of updating 2020. We also incorporate by reference into this description. All reports and other prospectus supplement additional documents that we may file with the SEC under Sections Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after Act, from the date of this prospectus but before supplement until all of the termination of securities offered by this prospectus supplement have been sold or the offering of these securities is otherwise terminated, provided, however, that information “furnished” under Item 2.02 or Item 7.01 of Form 8-K or other information “furnished” to the securities hereunder SEC which is not deemed filed is not incorporated by reference in this prospectus supplement and in the accompanying prospectus. Information that we subsequently file with the SEC as aforesaid will also be considered to be automatically update and may supersede information in this prospectus supplement and the accompanying prospectus and information that we previously filed with the SEC. You may obtain copies of any of these filings from us as described below, through the SEC or through the SEC’s website as described in “Where You Can Find More Information.” Documents incorporated by reference are available without charge, excluding all exhibits unless an exhibit has been specifically incorporated by reference into this prospectus from supplement, by writing or calling our Investor Relations Department at the date following address and telephone number. Investor Relations Gladstone Land Corporation 0000 Xxxxxxxxxx Xxxxx, Xxxxx 000 McLean, Virginia 22102 (000) 000-0000 WHERE YOU CAN FIND MORE INFORMATION Copies of our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and amendments, if any, to those reports filed or furnished with the SEC pursuant to Section 13(a) or 15(d) of the filing Exchange Act are available free of charge through our website at xxx.XxxxxxxxxXxxx.xxx. A request for any of these reports and documentsmay also be submitted to us by sending a written request addressed to Investor Relations, and will supersede the information herein; providedGladstone Land Corporation, however0000 Xxxxxxxxxx Xxxxx, Xxxxx 000, XxXxxx, XX 00000, or by calling our toll-free investor relations line at 0-000-000-0000. The SEC also maintains a website that all contains reports, exhibits proxy and information statements, and other information regarding issuers that we file electronically with the SEC at xxx.xxx.xxx. We have filed with the SEC a “furnishshelf” registration statement on Form S-3 under the Securities Act relating to the SEC will not securities that may be considered incorporated offered by reference into this the accompanying prospectus. We undertake to provide without charge to each person (including any beneficial owner) who receives Such prospectus is a copy part of this prospectusthat registration statement, upon written or oral request, a copy of but does not contain all of the preceding documents information in the registration statement. We have omitted parts of the registration statement in accordance with the rules and regulations of the SEC. For more detail about us and any securities that are incorporated may be offered by reference (other than exhibitssuch prospectus, unless you may examine the registration statement on Form S-3 and the exhibits are specifically incorporated by reference into these documents). You may request a copy of these materials filed with it at the locations listed in the manner set forth under the heading “Additional Information,” aboveprevious paragraph. Up to PROSPECTUS $150,000,000 1,000,000,000 Common Stock PROSPECTUS SUPPLEMENTPreferred Stock Warrants

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “‘‘incorporate by reference” ’’ information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documentsanother document filed separately with the SEC. The information SEC file number for the documents incorporated by reference in this prospectus is an important part of this prospectus001‑37717. The information documents incorporated by reference is considered to be a part of into this prospectus, and prospectus contain important information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplementyou should read about us. We incorporate The following documents are incorporated by reference the documents listed below that we have previously filed with the SECinto this document: ● · our Annual Report on Form 10-K 10‑K for the fiscal year ended December 31, 20162016 and filed with the SEC on February 23, 2017; · our Current Report on Form 8‑K filed with the SEC on January 26, 2017 and March 30, 2017; and CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. · the description of our common stock, which is registered under Section 12 of the Exchange Act, in our registration statement on Form 8‑A, filed with the SEC on March 811, 2017; ● our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 2017; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our Current Reports on Form 8-K filed with the SEC on February 28, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (other than any portions thereof deemed furnished and not filed); and ● the description of our common stock contained in our Registration Statement on Form 8-A, filed on April 14, 20152016, including any amendments thereto or reports filed for the purposes purpose of updating this such description. All We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8‑K and other documents exhibits filed on such form that we file are related to such items) that are filed by us with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii) after the date of this prospectus but before prior to the termination of the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, and will supersede the information herein; provided, however, that all offering. These documents include periodic reports, exhibits such as Annual Reports on Form 10‑K, Quarterly Reports on Form 10‑Q and other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectusCurrent Reports on Form 8‑K, as well as proxy statements. We undertake to will provide without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, without charge upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits which are specifically incorporated by reference into these such documents). You may request Requests should be directed to: Senseonics Holdings, Inc., Attn: Investor Relations, 00000 Xxxxxx Xxxxxxx Xxxxxxx, Germantown, MD 20876‑7005, telephone: (301) 515‑7260. Any statement contained herein or in a copy document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of these materials the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENTstatement.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” reference information from other documents that we file with it into this prospectusit, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important considered to be part of this prospectus. The Information in this prospectus supersedes information incorporated by reference is considered that we filed with the SEC prior to be a part the date of this prospectus, and while information that we file later with the SEC will automatically update and supersede the information contained in this prospectus and any accompanying prospectus supplementprospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have previously filed with the SEC: ● SEC (Commission File No. 001-36500): • our Annual Report on Form 10-K K, for the fiscal year ended December 31, 20162019, filed with the SEC on March 816, 20172020, as amended byAmendment No. 1 to our Annual Report on Form10-K/A, for the year ended December 31, 2019, filed with the SEC on April 29, 2020; ● • our Quarterly Reports Report on Form 10-Q Q, for the fiscal quarters quarter ended March 31, 20172020, filed with the SEC on May 911, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172020; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● • our Current Reports on Form 8-K filed with the SEC on February 28January 29, 2017, March 30, 2017, May 26, 2017, August 22, 2017, October 17, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 2020 (other than any portions thereof deemed furnished Items 2.02 and not filed7.01 and related exhibit), May 11, 2020 (including Item 2.02 and related exhibit) and June 26, 2020; and ● • the description of our common stock contained set forth in our Registration Statement on Form registration statement onForm 8-A, filed with the SEC on April 14June 16, 20152014, including any amendments thereto amendment or reports report filed for the purposes purpose of updating this such description. All We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form8-K and other documents exhibits filed on such form that we file are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC under pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act Act, including those made after the date of the initial filing of the registration statement of which this prospectus but before is a part and prior to effectiveness of such registration statement, until we file a post-effective amendment that indicates the termination of the offering of the securities hereunder made by this prospectus, which will also be considered to be incorporated by reference into become a part of this prospectus from the date of that such documents are filed with the filing of these reports SEC. Information in such future filings updates and documents, and will supersede supplements the information herein; provided, however, that all reports, exhibits and other information that we “furnish” to the SEC will not be considered incorporated by reference into provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier statements. We undertake to provide will furnish without charge to each person (person, including any beneficial owner) who receives , to whom a copy of this prospectusprospectus is delivered, upon written or oral request, a copy of any or all of the preceding documents that are incorporated by reference (other than exhibitsinto this prospectus but not delivered with the prospectus, unless the including exhibits that are specifically incorporated by reference into these such documents). You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. should direct any requests for documents to: CymaBay Therapeutics, Inc. Attn: Vice President, Finance 0000 Xxxxxxx Xxxx, Xxxxx 000 Newark, CA 94560 (000) 000-0000 15 Up to $150,000,000 75,000,000 Common Stock PROSPECTUS SUPPLEMENTPROSPECTUS

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE. The SEC allows SEC’s rules allow us to “incorporate by reference” information that we file with it into this prospectus supplement and the accompanying prospectus, which . This means that we can disclose important information to you by referring you to those documentsanother document. The information incorporated by reference is an important part of this prospectus. The information or deemed to be incorporated by reference is considered to be a part of this prospectusprospectus supplement, and information that we file later filed separately with the SEC subsequent to the date of this prospectus supplement and prior to the termination of the offering referred to in this prospectus supplement will automatically be deemed to update and supersede information contained in this prospectus and any accompanying prospectus supplementinformation. We incorporate by reference the The following documents listed below that we have previously filed with the SECSEC are incorporated by reference into this prospectus supplement except for any documents or portions thereof deemed to be “furnished” and not “filed” in accordance with SEC rules: ● our • Our Annual Report on Form F orm 10-K and 1 0-K/A for the fiscal year ended December 31, 2016, filed with the SEC 2020; • Our Quarterly Report on March 8, 2017; ● our Quarterly Reports on Form F orm 10-Q for the fiscal quarters quarter ended March 31, 2017, filed with the SEC on May 9, 2017, June 30, 2017, filed with the SEC on August 9, 2017 and September 30, 2017, filed with the SEC on November 8, 20172021; ● our Proxy Statement on Schedule 14A filed with the SEC on April 10, 2017; ● our • Our Current Reports on Form 8-K and Form 8-K/A filed with the SEC on February J anuary 5, 2021, January 28, 20172021, March 3029, 20172021, May 26J une 11, 20172 021, August 22J une 23, 20172021, October 17June 28, 2017, October 19, 2017, October 24, 2017 and November 27, 2017 (2021 other than any portions thereof deemed the information furnished pursuant to Item 7.01 and not filedExhibit 99.1), J uly 1, 2021, July 7, 2 021, J xxx 00, 2021 and J xxx 00, 2021; and ● the • The description of our common stock contained set forth in our Registration Statement the registration statement on Form F orm 8-AA registering our common stock under Section 12 of the Exchange Act, which was filed with the SEC on April 1425, 20152013, including any amendments thereto or reports filed for the purposes of updating this such description. All reports and other documents that we file with the SEC under (but not those that we furnish) pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus supplement but before prior to the termination of the offering of the securities hereunder will also covered hereby shall be considered deemed to be incorporated by reference into this prospectus from the date of the filing of these reports and documents, supplement and will automatically update and supersede the information herein; providedin this prospectus supplement, however, the accompanying prospectus and any previously filed documents. References in this prospectus supplement to documents incorporated by reference shall also include documents deemed to be incorporated by reference. Information that all reports, exhibits and other information that we is “furnishfurnished” to the SEC will shall not be considered deemed incorporated by reference into this prospectusprospectus supplement or the registration statement of which this prospectus supplement is part. We undertake Any statement made in a document incorporated or deemed to provide without charge be incorporated by reference into this prospectus supplement will be deemed to each person (including any beneficial owner) who receives a copy be modified or superseded for purposes of this prospectusprospectus supplement to the extent that a statement contained in this prospectus supplement, upon written or oral in any other subsequently filed document that is incorporated or deemed to be incorporated by reference into this prospectus supplement, modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. You can obtain any of the filings incorporated by reference into this prospectus supplement through us or from the SEC through the SEC’s website at xxx.xxx. Upon request, we will provide, without charge, a copy of any or all of the preceding reports and documents referred to above which have been incorporated by reference into this prospectus supplement. You should direct requests for these documents to: Tempest Therapeutics, Inc., Attn: Investor Relations, 0000 Xxxxxxxxx Xxxxx; Xxxxx 000 Xxxxx Xxx Xxxxxxxxx, XX 00000. Our reports and documents incorporated by reference herein may also be found in the “Investor Relations” section of our website at Xxxxxxxxx.xxx. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under “Incorporation of Certain Documents by Reference”) is not incorporated by reference into this prospectus supplement, and you should not consider it a part of this prospectus supplement, the accompanying prospectus or the registration statement of which they are a part. PROSPECTUS $250,000,000 Common Stock Preferred Stock Debt Securities Warrants Units Rights to Purchase Common Stock, Preferred Stock, Debt Securities or Units From time to time, we may offer up to $250,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions. This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement. Our common stock is traded on the Nasdaq Capital Market under the symbol “TPST.” On July 15, 2021, the last reported sale price of our common stock was $19.43 per share. We are a “smaller reporting company” under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See “Summary—Implications of Being a Smaller Reporting Company.” Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference (other than exhibitsinto this prospectus as described on page 3 of this prospectus. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The date of this prospectus is July 23, unless the exhibits are specifically incorporated by reference into these documents)2021. You may request a copy of these materials in the manner set forth under the heading “Additional Information,” above. Up to $150,000,000 Common Stock TABLE OF CONTENTS A BOUT THIS PROSPECTUS SUPPLEMENTi S UMMARY 1 R ISK FACTORS 3 S PECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 U SE OF PROCEEDS 4 D ESCRIPTION OF CAPITAL STOCK 5 D ESCRIPTION OF DEBT SECURITIES 9 D ESCRIPTION OF WARRANTS 16 D ESCRIPTION OF UNITS 19 D ESCRIPTION OF RIGHTS 20 L EGAL OWNERSHIP OF SECURITIES 22 P LAN OF DISTRIBUTION 26 L EGAL MATTERS 28 E XPERTS 28 W HERE YOU CAN FIND MORE INFORMATION 28 I NCORPORATION OF CERTAIN INFORMATION BY REFERENCE 29